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Atherosclerosis is an inflammatory disease characterized by accumulation of lipids in the inner layer 
of the arterial wall. During atherogenesis, various structures that are recognized as non-self by the 
immune system, such as modified lipoproteins, are deposited in the arterial wall. Accordingly, 
atherosclerotic lesions and blood of humans and animals with atherosclerotic lesions show signs of 
activation of both innate and adaptive immune responses. Although immune attack is initially a self-
protective reaction, which is meant to destroy or remove harmful agents, a chronic inflammatory state 
in the arterial wall accelerates atherosclerosis. Indeed, various modulations of the immune system of 
atherosclerosis-prone animals have provided us with convincing evidence that immunological 
mechanisms play an important role in the pathogenesis of atherosclerosis.  
 
This thesis focuses on the role of complement system, a player of the innate immunity, in 
atherosclerosis. Complement activation via any of the three different pathways (classical, alternative, 
lectin) proceeds as a self-amplifying cascade, which leads to the generation of opsonins, 
anaphylatoxins C3a and C5a, and terminal membrane-attack complex (MAC, C5b-9), all of which 
regulate the inflammatory response and act in concert to destroy their target structures. To prevent 
uncontrolled complement activation or its attack against normal host cells, complement needs to be 
under strict control by regulatory proteins. The complement system has been shown to be activated in 
atherosclerotic lesions, modified lipoproteins and immune complexes containing oxLDL, for instance, 
being its activators.  
 
First, we investigated the presence and role of complement regulators in human atherosclerotic 
lesions. We found that inhibitors of the classical and alternative pathways, C4b-binding protein and 
factor H, respectively, were present in atherosclerotic lesions, where they localized in the superficial 
proteoglycan-rich layer. In addition, both inhibitors were found to bind to arterial proteoglycans in 
vitro. Immunohistochemical stainings revealed that, in the superficial layer of the intima, complement 
activation had been limited to the C3 level, whereas in the deeper intimal layers, complement 
activation had proceeded to the terminal C5b-9 level. We were also able to show that arterial 
proteoglycans inhibit complement activation in vitro. These findings suggested to us that the 
proteoglycan-rich layer of the arterial intima contains matrix-bound complement inhibitors and forms 
a protective zone, in which complement activation is restricted to the C3 level. Thus, complement 
activation is regulated in atherosclerotic lesions, and the extracellular matrix is involved in this 
process. 
 
Next, we studied whether the receptors for the two complement derived effectors, anaphylatoxins C3a 
and C5a, are expressed in human coronary atherosclerotic lesions. Our results of 
immunohistochemistry and RT-PCR analysis showed that, in contrast to normal intima, C3aR and 
C5aR were highly expressed in atherosclerotic lesions. In atherosclerotic plaques, the principal cells 
expressing both C3aR and C5aR were macrophages. Moreover, T cells expressed C5aR, and a small 
fraction of them also expressed C3aR, mast cells expressed C5aR, whereas endothelial cells and 
subendothelial smooth muscle cells expressed both C3aR and C5aR. These results suggested that 
intimal cells can respond to and become activated by complement-derived anaphylatoxins.  
 
Finally, we wanted to learn, whether oxLDL-IgG immune complexes, activators of the classical 
complement pathway, could have direct cellular effects in atherogenesis. Thus, we tested whether 
oxLDL-IgG immune complexes affect the survival of human monocytes, the precursors of 
macrophages, which are the most abundant inflammatory cell type in atherosclerotic lesions. We 
found that OxLDL-IgG immune complexes, in addition to transforming monocytes into foam cells, 
promoted their survival by decreasing their spontaneous apoptosis. This effect was mediated by cross-
linking Fcγ receptors with ensuing activation of Akt-dependent survival signaling. Our finding 
revealed a novel mechanism by which oxLDL-IgG immune complexes can directly affect the 






Cardiovascular diseases are the leading cause of death in the Western world, and they are also 
expected to be the main cause of global death within the next 15 years, since their prevalence 
is rapidly increasing even in the developing countries. Atherosclerosis (Greek ‘athero’ = 
gruel/paste; ‘sclerosis’ = hardening) is the most common underlying pathologic process 
leading to cardiovascular morbidity and mortality. It is a slow, complex process characterized 
by accumulation of lipids and thickening of the inner layer of the arterial wall, which, in its 
earliest form, appears to be present even at the fetal stage, and evolves slowly over decades. 
Atherosclerosis of coronary arteries may lead to compromised blood flow and oxygen supply 
to the myocardium. This may cause clinical symptoms due to chronic narrowing of the lumen 
(stable angina) or abrupt plaque erosion or rupture with ensuing thrombus formation (unstable 
angina, myocardial infarction).  
 
Hypercholesterolemia is a major risk factor for this disease, and cholesterol has been shown to 
be an absolute prequisite for lesion initiation and progression. In 1913, an experimental 
pathologist named Anitschkow found out that diet-induced hypercholesterolemia in rabbits 
leads to the generation of vascular lesions resembling human atherosclerosis. 
Hypercholesterolemia, and other ‘traditional risk factors’ such as tobacco smoking, 
hypertension, diabetes, male gender, age, and family history define much of the risk of the 
disease. However, many newly found ‘non-traditional risk factors’ such as inflammation are 
emerging and are considered to be of importance in the pathophysiology of atherosclerosis.  
 
More than a century ago already, Dr. Rudolf Virchow suggested that the generation of an 
atheroma results from an inflammatory process in the intima, but this view was ignored for 
decades, while the role of cholesterol dominated the scientific thinking. During the recent 
decades, however, much attention has been paid to inflammatory and immune mechanisms in 
the pathogenesis of atherosclerosis, and it has become apparent that these mechanisms play an 
important role in modulating the course of the disease. The current concept suggests that, 
during atherogenesis, various antigens, i.e. structures that are recognized as non-self by the 
immune system, are generated or retained in the intima and trigger an inflammatory and 
immune response against them. Thus, atherosclerosis has come to be regarded as a chronic 
inflammatory disease.  
 
The purpose of the present work was to examine the activation of immune mechanisms in 
atherosclerotic lesions with a specific focus on the complement system and the role of 
immune complexes containing oxidized LDL.  
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II LITERATURE REVIEW 
 
 
1 Pathogenesis of atherosclerosis 
 
1.1 Normal arterial intima 
 
The arterial wall consists of three layers: intima, media and adventia (Fig. 1). Intima is the 
innermost layer of the arterial wall, separated from the vacular lumen and circulating blood by 
only a single layer of endothelial cells. The endothelium, residing at the critical interface 
between blood flow and the arterial wall, functions as a permeability barrier, forms a 
thromboresistant surface, and attends to the regulation of vascular tone by producing 
prostacyclin, nitric oxide, and endothelin. The intima is composed of two layers; a superficial 
proteoglycan-rich layer and a deeper musculoelastic layer. Often, these layers can only be 
recognized in areas of adaptive intimal thickening (see later). The extracellular matrix of the 
superficial proteoglycan-rich layer is mainly composed of chondroitin sulfate-rich 
proteoglycan versican, and to a lesser extent, two smaller leucine-rich dermatan sulfate 
proteoglycans called decorin and biglycan (reviewed by Williams 2001) The matrix in this 
area also contains some collagen, mainly types I and III, elastin, and glycoproteins (Stary et 
al. 1992). The main sources of extracellular matrix are rough endoplasmic reticulum-rich 
smooth muscle cells of synthetic phenotype located scattered in the subendothelial region. In 
addition, some contractile, myofilament-rich smooth muscle cells are also present. The 
subendothelial space also contains some macrophages, mast cells, and T cells (Kaartinen et al. 
1994a). The deeper musculoelastic layer contains a large number of myofilament-rich, 
contractile smooth muscle cells, which are organized as close layers. The musculoelastic layer 
contains more collagen than the proteoglycan-rich layer and is rich in elastic fibers. The 
intima is separated from the middle layer of the vessel wall, the media, by continuous elastic 
lamina, called internal elastic lamina (IEL).  
 
Even without any signs of atherosclerosis, the intima of human epicardial coronary arteries is 
thickened in response to changes in physiological factors such as increased tension or 
disturbance of shear stress in the vessel wall. These adaptive intimal thickenings can be either 
diffuse or eccentric. In general, intimal thickening in coronary arteries is diffuse, and 
eccentric intimal thickening typically only occurs at the branching points of the arteries, 
involving half of the vessel circumference. Intimal thickening starts during fetal life, and all 
individuals have such thickenings at the time of birth (Stary et al. 1992). 
 
 
1.2 Morphological changes during atherogenesis 
 
The same mechanical forces that give rise to intimal thickenings also enhance the influx of 
plasma lipoproteins and other circulating molecules into the arterial intima. Thus, lesions 
evolve first and more rapidly in atherosclerosis-prone areas with eccentric intimal thickening 
of the vessel wall (Stary 1989). Based on the morphological changes observed in the vessel 
wall, especially in the intima, during the pathogenesis of atherosclerosis, lesions have been 
classified into types I-VIII by American Heart Association (AHA) (Fig. 1). Initial type I 
lesions are characterized by an increased number of macrophages, organized as small groups, 
which have been transformed into foam cells upon the uptake of lipids (Stary et al. 1994). 
When lipid-filled macrophages and smooth-muscle cells become more numerous and are 
organized in layers, the lesions are classified as type II lesions. In areas of thin intima, these 
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changes may be visible to the naked eye as flat, yellow-colored streaks in the inner surface of 
arteries, and they are called fatty streaks. In contrast, when colocalized with adaptive intimal 
thickening, foam cells locate deeper in the intima, in which case the changes might be 
invisible to the naked eye. In type II coronary lesions, the numbers of macrophages, T 
lymphocytes, and mast cells are increased (Kaartinen et al. 1994a). These minimal changes do 
not disrupt the normal structure of the arterial wall, presumably stabilize without any 
additional stimulus, and are clinically silent. Early lesions (types I and II) are typically present 
in children, but are also found in adults, especially in areas that are resistant to atherosclerosis. 
Type II lesions that locate in highly-susceptible, atherosclerosis-prone areas may progress to 
type III lesions, which are intermediate lesions between early and advanced atherosclerotic 
lesions. These lesions, which are present from young adulthood onward, are characterized by 
the accumulation of lipids as small separate pools in the extracellular space between smooth 
muscle cells, disrupting the space between closely adjoining smooth muscle cells in the 
intima.  
 
With the progression of atherosclerosis, typically from the third decade of life onward, the 
small lipid pools of type III lesions confluence into a larger, more disruptive extracellular 
lipid core, a hallmark type IV lesion (atheroma). The lipid derives not only from the free lipid 
droplets entered from plasma, but also from the remnants of dying foam cells. The lipid core 
may also contain cholesterol crystals and calcium particles. The intima overlying the core is 
usually of the same thickness as in type I and II lesions and contains macrophages and smooth 
muscle cells with or without intracellular lipids as well as T lymphocytes and mast cells. 
These lesions clearly thicken the arterial wall, but they may not diminish the diameter of the 
vascular lumen, since the vessel wall may first slightly expand outward, showing 
compensatory remodeling. In response to tissue disruption, intimal smooth-muscle cells start 
to proliferate and form new connective tissue matrix, especially collagen. This leads to 
thickening of the superficial intima overlying the lipid core, and consequently, in the 
formation of a fibrous cap, which separates the lipid core from the vessel lumen (type V 
lesion, fibroatheroma) (Stary et al. 1995). These new layers oppose the outward expansion, 
and may narrow down the vessel lumen. A report by Virmani and coworkers (Virmani et al. 
2000) divided type IV-V atheromas based on the thickness of the connective tissue layer 
covering the lipid core, i.e. the fibrous cap. “The thin fibrous cap atheromas” (cap <65 µm 
thick) are characterized by a loss of smooth muscle cells and extracellular matrix and 
typically have a large underlying lipid core and are most likely to rupture.  
 
Lesions complicated by a surface defect (rupture, erosion, calcified nodule) and thrombosis 
are classified as type VI lesions. The thrombus may cause clinical symptoms, such as 
myocardial infarction, unstable angina pectoris, or sudden coronary death, but it may also 
disappear without symptoms. Data suggest that 60% of sudden coronary deaths result from a 
rupture and subsequent thrombus formation, whereas erosions are the underlying cause of 
40% of thrombotic sudden coronary deaths (van der Wal et al. 1994). In plaque rupture, the 
fibrous cap is disrupted, usually at its weakest point, i.e. the shoulder region, and the luminal 
thrombus that develops is in communication with the lipid-rich necrotic core. The 
susceptibility of lesions to rupture is greatly influenced by the composition and structure of 
the underlying lesion. Ruptured lesions typically have an extensive necrotic core, a thin 
fibrous cap, scant smooth muscle cells, and large infiltration of inflammatory cells, which 
may further weaken the cap by producing toxic substances and matrix-degrading enzymes 
(Naghavi et al. 2003; van der Wal et al. 1994). In these plaques, moreover, vasa vasorum are 
typically present within the plaque and adventitia. These neovessels may contribute to 
destabilization of the plaque, since intraplaque hemorrhage has been shown to increase 
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significantly the size of the necrotic core (Kolodgie et al. 2003). Plaque erosion is 
characterized by superficial erosions, in which typically only the endothelial cell layer is 
detached. The intima underlying the erosion shows various compositions; some have 
characteristics of type III lesions, some contain a lipid core, and yet some others are entirely 
fibrous. In addition, especially in younger patients and women, the intima underlying erosions 
usually contains smooth muscle cells and proteoglycans. The results regarding the role of 
inflammatory process in erosion are controversial (Farb et al. 1996; van der Wal et al. 1994). 
The least frequent cause of thrombotic events, calcific nodule, refers to disruption of the 
endothelium/thin fibrous cap overlying a heavily calcified plaque.  
 
Histological evidence suggests that complicating episodes may occur in succession. During 
recovery, fissures are sealed, the thrombus is organized as part of the growing plaque, and 
endothelial cells overgrow the thrombus at the lumen. This “healing” process is a typical 
mechanism for plaque growth and may also lead to the formation of advanced plaques, in 
which calcification (type VII lesion) or fibrous tissue (type VIII lesion) predominates. 





Figure 1. Structure of the arterial wall and histolocigal classification of atherosclerotic lesions (according 
to the American Heart Association). Adapted from Stary et al. (1995). 
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1.3 Retention and modification of LDL during atherogenesis 
 
Infiltration and accumulation of atherogenic lipoproteins in the arterial intima constitutes a 
central pathogenic process in atherogenesis (reviewed by Williams & Tabas 1995). General 
view suggests that accumulation of LDL in atherosclerosis-prone areas of the arterial tree is 
not dependent on increased permeability of the endothelium or an increased rate of lipoprotein 
entry into the arterial wall, but it results mainly from increased retention of lipoproteins in the 
intima in these disease-prone areas (Schwenke & Carew 1989). Upon entering the arterial 
intima from circulation, LDL particles become entrapped in the tight extracellular matrix 
network of the intima and also bind to the components of the matrix, especially to 
proteoglycans. Interestingly, in vitro studies have shown that binding of LDL to 
proteoglycans is increased when proteoglycans originate from atherosclerotic-prone areas of 
the arterial tree (Cardoso & Mourao 1994). This binding is dependent on the interaction 
between positively charged lysine and arginine residues of apoB-100 of LDL and negatively 
charged glycosaminoglycans of proteoglycans. More specifically, Boren and coworkers 
showed that, when lysine3363 in apoB was replaced by glutamic acid, the binding of LDL to 
proteoglycans was severely defective (Boren et al. 1998). Moreover, transgenic mice 
expressing the mutated apoB-100 that does not bind to proteoglycans show strongly retarded 
development of atherosclerosis (Skålen et al. 2002), which clearly demonstrates the 
importance of LDL-proteoglycan interaction and lipoprotein retention in early atherogenesis. 
In addition to this direct binding of apoB to proteoglycans, LDL may be linked to PGs by 
molecules such as LPL, which is locally produced by e.g. macrophages (reviewed by 
Pentikäinen et al. 2002). Entrapment and retention of LDL by the extracellular matrix 
prolongs its residence in the intima and predisposes it to modifications by enzymes and agents 
secreted by intimal cells (Pentikäinen et al. 1997). In vitro studies have shown that various 
modifications of LDL (oxidation, proteolysis, and phospholipolysis) can disrupt the surface 
structure of LDL particles and lead to aggregation and fusion of lipoprotein particles 
(Pentikäinen et al. 1996). Such modification-induced changes appear to be required for the 
accumulation of LDL-derived lipids both extra- and intracellularly in the arterial intima. 
Indeed, the arterial intima has been shown to contain extracellular lipid droplets and pools of 
lipids, and when extracted they possess qualities that suggest that they derive from plasma 
LDL particles that have undergone modifications of various types (reviewed by Öörni et al. 
2000). Furthermore, modified lipoproteins have been detected in the arterial wall by 
immunohistochemical methods (Torzewski et al. 1998b; Jurgens et al. 1993). Modifications 
of LDL also promote its intracellular accumulation, since macrophages and smooth muscle 
cells recognize and take up modified LDL via various scavenger receptors. In contrast to the 
uptake of native LDL, cholesterol uptake via scavenger receptors is not subject to negative 
feedback regulation, and it thus leads to uncontrolled endocytosis and transformation of cells 
into lipid-filled foam cells (Goldstein et al. 1979).  
 
Of the different modifications of LDL, oxidation was long considered the single most 
important modification with regard to atherogenesis. As described above, oxidation of LDL 
promotes the accumulation of LDL both extra- and intracellularly, but it also changes LDL 
into immunogenic and pro-inflammatory particles (reviewed by Hörkkö et al. 2000). In the 
oxidative process of LDL, both lipids and apoB-100 are oxidized. Oxygen radicals attack 
unsaturated fatty acids residues in lipoprotein, notably in surface phospholipids, and this lipid 
peroxidation leads to the release of aldehyde fragments (malondialdehyde; MDA and 4-
hydroxynonenal; 4-HNE), which may react with apoB-100 in LDL by binding to lysine 
residues. In addition, reactive oxidation products derived from phospholipids such as POVPC 
(1-palmitoyl-2-(5’-oxovaleroyl)-sn-glycero-phosphocholine) can form covalent adducts with 
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apoB-100 of LDL (reviewed by Hörkkö et al. 2000). Circulating LDL, despite the potent 
antioxidant capacity of plasma, has been shown to contain oxidized epitopes (Palinski et al. 
1996; Tsimikas et al. 2005). While the origin of these circulating oxidized lipoprotein 
particles remains unclear, convincing evidence indicates that oxidative modification of LDL 
occurs in the microenvironments of atherosclerotic arterial wall, where LDL is no longer 
efficiently protected by antioxidants of plasma. Indeed, LDL isolated from atherosclerotic 
lesions, but not from normal intima, shows signs of oxidation, i.e. increased electrophoretic 
mobility, and reacts with the antibody against MDA-modified LDL (Ylä-Herttuala et al. 
1989). In addition, immunohistochemical methods have shown oxidation specific epitopes in 
LDL in atherosclerotic lesions (Palinski et al. 1996; Palinski et al. 1989; Jurgens et al. 1993). 
Regarding the mechanisms of LDL oxidation in vivo, various alternatives have been 
proposed, and it is known that various cell types present in atherosclerotic lesions are able to 
mediate lipid oxidation in vitro (reviewed by Steinberg 1997). While transition metal ions 
(Cu2+ or Fe2+) have been suggested to play only a minor role in the oxidation of LDL in 
atherosclerotic lesions, more evidence exists for the role of 15-lipoxygenase, 
myeloperoxidase, and reactive nitrogen species in this process (reviewed by Heinecke 1997). 
All these agents are capable of causing LDL oxidation in vitro, and they are present in 
atherosclerotic, but not in normal, arterial wall. In addition, markers of oxidation by 15-
lipoxygenase, myeloperoxidase and reactive nitrogen species have been detected in 
atherosclerotic lesions, and LDL isolated from atherosclerotic lesions has been shown to 
contain signs of oxidation by these agents (Heinecke 1997).  
 
In addition to oxidative enzymes, atherosclerotic lesions also contain various proteolytic and 
lipolytic enzymes capable of non-oxidatively modifying LDL either at neutral or acidic pH. 
Proteolytic modifications may degrade the apoB-100 moiety of LDL, whereas lipases can 
hydrolyze phospholipids, triglycerides and cholesterol esters of LDL. Both proteolysis and 
phospholipolysis of LDL may lead to changes in the surface structure of LDL, which, 
similarly to oxidation, may lead to aggregation and fusion of lipoprotein particles (reviewed 
by Öörni et al. 2000). Proteases present in atherosclerotic lesions include mast cell-derived 
tryptase and chymase (Kaartinen et al. 1994b), plasma-derived plasmin (Grainger et al. 1994), 
kallikrein (Cerf et al. 1999), thrombin (Smith et al. 1996), various matrix metalloproteinases 
(reviewed by Garcia-Touchard et al. 2005), and lysosomal proteases including cathepsins G, 
S, K, F and D (Legedz et al. 2004; Sukhova et al. 1998; Öörni et al. 2004; Hakala et al. 
2003). In addition, various lipases such as acid sphingomyelinase (Marathe et al. 1999), 
phospholipase A2 (PLA2)(Romano et al. 1998), carboxyl ester lipase (Li & Hui 1998), and 
lysosomal acid lipase (Hakala et al. 2003) are present in the intima. To support their role in 
the modification of LDL in vivo, LDL extracted from arterial intima shows signs which 
suggest modification by both proteases and lipases (Öörni et al. 2000). In addition to these 
changes in lesion-derived LDL, enzymatically modified LDL has also been detected in 
atherosclerotic lesions by immunohistochemical methods. In these experiments, Torzewski 
and coworkers created an antibody against LDL modified with trypsin, neuraminidase, and 
cholesterol esterase (E-LDL), a modification that creates LDL with properties akin to lipids 
extracted from atherosclerotic lesions (Bhakdi et al. 1995), and found LDL containing such 
modified epitopes in human atherosclerotic lesions (Torzewski et al. 1998b).  
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2 Immune mechanisms in atherosclerosis 
 
 
There is potent evidence to indicate that the immune system plays an important role in 
atherogenesis and its complications. Very soon after the introduction of an atherogenic diet, 
the endothelium of rabbit vessel wall shows attached leukocytes (Poole & Florey 1958), and 
the atherosclerotic lesions of animal models and humans have been shown to contain 
infiltrates of immune cells, particularly macrophages and T cells (Jonasson et al. 1986). This 
accumulation of immune cells during early atherogenesis suggests that immune activation 
toward plaque material plays a role in atherogenesis. In addition, the sites of plaque rupture 
contain activated macrophages, T cells, mast cells, and neutrophils (Kovanen et al. 1995; van 
der Wal et al. 1994; Naruko et al. 2002), suggesting that activation of the immune system also 
has implications for the later stages of the disease. In addition to inflammatory cells, 
atherosclerotic lesions contain other signs of immune activation, such as activation products 
of the complement system (Vlaicu et al. 1985a). Furthermore, circulating autoantibodies 
against plaque material and their correlation with cardiovascular diseases strongly support the 
role of immune activation in atherogenesis (reviewed by Nilsson & Kovanen 2004). Finally, 
the most convincing evidence derives from experimental studies demonstrating that specific 
immune-based interventions can influence lesion progression in animal models.  
 
Both innate and adaptive immune systems are activated in atherosclerotic lesions and act in 
concert to destroy foreign or altered self structures. Despite the established division into 
innate and adaptive immunity, it is worth remembering that there is a vast amount of cross-
talk between these systems and simultaneous activation of both cellular and humoral types of 
response. Although, initially, an immune attack is regarded as a self-protective reaction meant 
to destroy the harmful agents, chronic inflammation in the arterial wall appears to be 
detrimental and self-perpetuating inflammatory state leading to aggravation of atherosclerosis 
and even rupture or erosion of plaque.  
 
 
2.1 What are the triggers of the immune response in atherosclerotic plaques? 
 
The nature of the process and agents that elicit a localized inflammatory and immune 
response in atherosclerotic lesions is not totally clear. It is likely that, once lesion formation 
has begun, various antigens are generated within the atherosclerotic lesion. Indeed, Paulsson 
and coworkers showed that atherosclerotic lesions of apoE-/- mice show preferential 
expression of TCR-variable regions, suggesting oligoclonal rather than polyclonal expansion 
of T cells and indicating that a limited number of antigens induce an immune response in 
atherosclerotic plaques (Paulsson et al. 2000). Regarding possible antigens, modified 
lipoproteins are obvious candidates. In addition, various other candidates, including 
endogenous agents such as β2-glycoprotein 1 and heat shock proteins, as well as antigens 
derived from exogenous pathogens have been proposed. 
 
2.1.1 Oxidized LDL 
 
The most extensive data obtained so far support a role for oxLDL as a trigger of an immune 
response in atherosclerotic lesions (reviewed by Hörkkö et al. 2000). When LDL accumulates 
extracellularly in arterial intima, it is predisposed to oxidative modification (see section 
Retention and modification of LDL during atherogenesis) leading to the generation of a 
variety of highly immunogenic neo-determinants, which can trigger the activation of both 
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innate and adaptive types of immune responses. Regarding innate immunity, oxLDL has been 
shown to bind to various pattern recognition receptors (reviewed by Miller et al. 2003a). In 
addition, oxLDL antibodies cloned from the spleens of hypercholesterolemic apoE-/- mice 
have been shown to belong to the class of highly conserved natural antibodies of innate 
immunity, and they immunostain both rabbit and human atherosclerotic lesions (Palinski et al. 
1996). There is also evidence about the activation of an adaptive immune response against 
oxLDL. Indeed, 15% of T cells isolated from human plaques and cloned and expanded in 
culture proliferated in response to oxLDL in a HLA-DR-dependent manner (Stemme et al. 
1995), and human peripheral T cells have also been shown to become activated by oxLDL 
(Frostegård et al. 1992). Further, the spleens of apoE-/- mice give rise to oxLDL-specific T 
cell lines that display strong immunity to oxLDL (Caligiuri et al. 1999). In addition, 
autoantibodies against oxLDL have been detected in the plasma of hypercholesterolemic 
experimental animals, in which their levels correlated with the severity of the atherosclerosis 
(Palinski et al. 1995b). In humans, in contrast, both positive and negative correlations 
between the levels of oxLDL-autoantibodies and cardiovascular diseases have been reported 
(see section OxLDL autoantibodies of adaptive immunity). Moreover, immunization studies 
have shown that immunization of atherosclerosis-prone animals with prepararations of 
oxLDL decreased the size of lesions (see section Effects of immune system in atherogenesis). 
Interestingly, the transfer of purified CD4+ cells from oxLDL-immunized mice to 
immunodeficient apoE-/- mice aggravated atherosclerosis more than T cells from mice 
immunized with KLH (Zhou et al. 2006).   
 
2.1.2 β2-glycoprotein 1 
 
β2-glycoprotein 1 (β2-GP1) is a highly glycosylated plasma protein, of which about 40% 
circulates in association with lipoproteins of various classes, and complexes between β2-GP1 
and oxLDL have also been described (Kobayashi et al. 2003). β2-GP1 binds avidly to 
negatively charged phospholipids surfaces and is suggested to be a major target for 
autoimmune type antiphospholipids antibodies (McNeil et al. 1990). Furthermore, Hörkkö 
and coworkers suggested that, analogous to LDL oxidation, some of the epitopes for 
autoimmune antibodies are generated, when oxidized phospholipids form covalent adducts 
with associated proteins, such as β2-GP1, and thus form neoepitopes recognized by 
antiphospholipid antibodies (Hörkkö et al. 1997; Hörkkö et al. 2001). β2-GP1 is present in 
human atherosclerotic lesions, where it is mainly found in the subendothelial area colocalized 
with CD4+ T lymphocytes (George et al. 1999a). Studies on experimental animals have 
shown that immunization of atherosclerosis-prone mice with human β2-GP1 induces both 
cellular and humoral immune responses against β2-GP1 and leads to acceleration of aortic 
atherosclerosis (George et al. 1998a; Afek et al. 1999). Furthermore, transfer of lymph node 
cells reactive for human β2-GP1 to LDL-receptor-deficient mice promoted fatty streak 
formation (George et al. 2000). These findings suggest that an immune response against β2-
GP1 may promote atherogenesis. Indeed, antibodies against β2-GP1 (Ranzolin et al. 2004; 
Romero et al. 1998) as well as antiphospholipids antibodies in general (Bili et al. 2000; 
Vaarala et al. 1995) have been shown to correlate positively with cardiovascular disease and 
its complications.  
 
2.1.3 Heat shock proteins 
 
Heat shock proteins (HSPs) act as chaperones and are involved in protein folding, 
intracellular transport, and controlled breakdown of proteins, and they are produced in large 
amounts by injured cells (reviewed by Xu 2002). HSPs are highly conserved in evolution, and 
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accordingly, human HSP60 can cross-react immunologically with mycobacterial HSP65 and 
chlamydial HSP60. Thus, protective humoral and cellular immune responses toward micro-
organisms may be misdirected against human HSPs expressed by the stressed cells of the 
arterial wall (Perschinka et al. 2003; Mayr et al. 1999). Indeed, various risk factors of 
atherosclerosis, such as hemodynamic stress and oxLDL can induce HSP60 and also HSP70 
expression in endothelial cells (Hochleitner et al. 2000; Zhu et al. 1994), macrophages 
(Frostegård et al. 1996), and smooth muscle cells (Xu et al. 2000; Zhu et al. 1995). 
Accordingly, HSP60 and also HSP70 are highly expressed in various cell types in 
atherosclerotic lesions of humans and animal models of atherosclerosis, and their expression 
correlates with the severity of atherosclerosis. To support the role of HSPs as an antigenic 
structures in atherogenesis, a number of studies have shown that antibodies against either 
human or microbial HSPs are associated and predict cardiovascular disease and its 
complications (reviewed by Xu 2002). In addition, human carotid atherosclerotic plaques 
have been shown to contain a population of T cells that specifically respond to chlamydial 
HSP60 (Mosorin et al. 2000; Curry et al. 2000), and recently a population of CD4+ T cells 
reacting with human HSP60 was also demonstrated in such lesions (Benagiano et al. 2005). 
Moreover, parenteral immunization with HSP60/65 has been shown to aggravate 
atherosclerosis in rabbit and mouse models of atherosclerosis (Afek et al. 2000; George et al. 
1999b; Xu et al. 1992) and to lead to vascular inflammation and infiltrates of HSP60 reactive 
T cells (Xu et al. 1993). In addition to activating an adaptive immune response, HSPs have 
also been shown to directly activate the innate immune response via Toll-like receptors (TLR) 
(Ohashi et al. 2000). 
 
2.1.4 Infectious agents 
 
The role of infectious agents as antigens in atherogenesis is supported by the presence of 
various infectious agents in the arterial wall and by the seroepidemiological studies reporting 
an association between pathogen-specific antibodies and atherosclerosis. In this regard, most 
interest has focused on the role of Chlamydia pneumoniae, Herpes viruses, Helicobacter 
pylori, and oral pathogens. Yet, it is not clear whether the pathogens in the arterial wall are 
causal agents or only “innocent bystanders”, and it has also been suggested that chronic low-
grade infection or recurrent infections, even at extravascular sites of the body, may increase 
the risk for atherosclerosis (Kiechl et al. 2001). Furthermore, it is also possible that the risk of 
atherosclerosis is not increased by a single infectious agent, but rather the total number of 
pathogens to which a person is exposed during his or her lifetime, i.e, the “bacterial burden” 
(Zhu et al. 2000). In line with this hypothesis, a recent study demonstrated that the 
atherosclerotic lesions of patients with coronary heart disease contained highly diverse 
bacterial DNA (Ott et al. 2006). However, lipid-driven animal models have established that 
infectious agents are not necessary for lesion development, but this does not rule out the 
possibility, that infectious agents or an immune response toward them could still have a 
modifying function in atherosclerosis (Wright et al. 2000).  
 
Of the above-mentioned pathogens, Chlamydia pneumoniae is the most extensively studied. It 
is an intracellular pathogen, which is suggested to be transported to atherosclerotic lesions by 
circulating monocytes from the respiratory tract. Indeed, C. pneumoniae has been detected in 
atherosclerotic plaques by various techniques, including immunohistochemistry, PCR, 
electron microscopy, and in situ hybridization, and it has also been successfully cultured from 
these lesions, while it has been very rarely demonstrated in healthy arterial wall (reviewed by 
Boman & Hammerschlag 2002). Furthermore, human atherosclerotic lesions have been 
shown to contain T cells that recognize C. pneumoniae (Mosorin et al. 2000; Curry et al. 
Literature Review 18 
2000), suggesting that this pathogen may activate the immune response locally in plaque. 
Antibodies against C. pneumoniae are prevalent in the population, and the results regarding 
their role and possible predictive value in atherosclerosis have been controversial. Although a 
vast number of cross-sectional studies initially demonstrated a strong correlation between 
elevated titers of anti-chlamydial antibodies and cardiovascular diseases, more recent 
prospective studies as well as their meta-analysis failed to detect such association 
(Bloemenkamp et al. 2003; Danesh et al. 2000), suggesting that a strong causal relationship is 
unlikely. This is in accordance with the recent trials examining the effect of anti-chlamydial 
antibiotic treatment on the clinical endpoints of cardiovascular diseases, which failed to 
demonstrate a beneficial role for this therapy in secondary prevention (Andraws et al. 2005). 
However, these negative results do not fully exclude a role of C. pneumoniae infection in 
atherogenesis, since C. pneumoniae may remain in a dormant, intracellular phase for long 
periods, during which it is resistant to eradication by the immune system as well as by 
antibiotic therapy. Indeed, various studies on experimental animals have shown that C. 
pneumoniae infection, superimposed on hypercholesterolemia, accelerates the development of 
atherosclerosis (Moazed et al. 1999; Laitinen et al. 1997; Muhlestein et al. 1998; Pislaru et al. 
2003), although contradictory results have also been reported (Aalto-Setälä et al. 2001; 
Caligiuri et al. 2001). In addition, a very recent study showed that, during acute coronary 
syndrome, levels of both chlamydial lipopolysaccharide and CRP were increased and showed 
significant correlation (Tiirola et al. 2006). Their decrease after coronary event suggested that 
chlamydial lipopolysaccharide was released from arterial wall during event and participated in 
the induction of CRP production. 
 
The interest in oral pathogens in the pathogenesis of atherosclerosis was inspired by the 
finding that patients with periodontal disease have a higher incidence of complications of 
atherosclerosis (Scannapieco et al. 2003). Similarly, elevated antibody levels against a 
periodontal pathogen, Porphyromonas gingivalis, have correlated with cardiovascular disease 
(Pussinen & Mattila 2004). Although it has been suggested that oral infections may only 
reflect confounding common risk factors of atherosclerosis or provide a focus of chronic 
inflammation in the body, recent evidence indicates that various periodontal pathogens are 
present in atherosclerotic lesions (Haraszthy et al. 2000) and can locally activate an immune 
response, as demonstrated by the presence of P. gingivalis-reactive T cells in plaques (Choi et 
al. 2002). Finally, P. gingivalis has been shown to accelerate atherosclerosis in animal models 
(Lalla et al. 2003; Jain et al. 2003; Li et al. 2002).  
 
In addition to Chlamydia pneumoniae and periodontal pathogens, Helicobacter pylori and 
various viruses belonging to the herpesvirus family (HSV-1,-2, EBV, and CMV) have been 
detected in human lesions (Kaplan et al. 2005; Raza-Ahmad et al. 1995; Ibrahim et al. 2005). 
Furthermore, some reports exist on the correlation between seropositivity against EBV or 
Helicobacter pylori and cardiovascular diseases (Mendall et al. 1994; Musiani et al. 1990) 
and on the correlation between seropositivity for CMV and progression of atherosclerosis, 
especially in transplanted hearts or after coronary atherectomy (Danesh et al. 1997). 
Atherosclerotic lesions have also been shown to contain a T cell population that responds to 
EBV in a MHC class II-restricted manner (Boer de et al. 2005), and cytomegalovirus 
infection has been shown to increase atherosclerosis in apoE-/- mice (Hsich et al. 2001).  
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2.2 Infiltration of inflammatory cells into arterial intima 
 
Infiltration of leukocytes, notably monocytes and lymphocytes, into the developing lesions is 
one of the initial events in atherogenesis. The process of leukocyte recruitment into the 
arterial wall is a multi-step process, which is dependent on the interaction between leukocytes 
and endothelium as well as the expression of various chemokines. Infiltration of inflammatory 
cells into the intima seems to be important for atherogenesis, since disruption of this process 
by genetic deletion of endothelial adhesion molecules, leukocyte integrins, or chemotactic 
molecules and their receptors leads to decreased atherosclerosis in animal models (see Table 
4). 
 
Experimental evidence shows that, very soon after the introduction of an atherogenic diet, 
leukocytes are attached to the endothelium of rabbit vessel wall (Poole & Florey 1958). In this 
initial step, leukocytes bind to endothelial P- and E-selectins, resulting in tethering and rolling 
of the cells along the vessel wall. Next, leukocytes adhere more firmly to the endothelium. 
This step is dependent on the activation of leukocytes by chemoattractants released from the 
tissues followed by binding of leukocyte integrins i.e. very late antigen-4 (VLA-4) and 
lymphocyte function-associated antigen-1 (LFA-1) to their endothelial counterparts, i.e. 
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-
1), respectively. Regarding atherosclerosis, endothelial cells have been shown to express 
VCAM-1 and ICAM-1 selectively in areas prone to lesion formation (Cybulsky & Gimbrone 
1991; Nakashima et al. 1998). In addition, both selectins and VCAM-1 and ICAM-1 are 
strongly expressed in endothelium overlying developing plaques, whereas expression is much 
lower or non-existent in endothelium overlying healthy intima (Davies et al. 1993; 
Nakashima et al. 1998). Interestingly, the expression of these adhesion molecules by 
endothelial cells has been shown to increase in response to hemodynamic stress and also in 
response to plaque material, notably components formed during lipoprotein oxidation (Vora et 
al. 1997; Walpola et al. 1995; Frostegård et al. 1991; Watson et al. 1997). Recently, these 
early events of leukocyte-endothelium interactions have also been investigated in vivo. By 
using the modern technique of intravital microscopy, Eriksson et al. demonstrated that, in a 
mouse model, the rolling of leukocytes occurred on the periphery of atherosclerotic lesions 
but not in normal vessel wall, and that these leukocyte-endothelial interactions were transient 
and critically dependent on the expression of endothelial selectins (Eriksson et al. 2001). In 
addition to this integrin-dependent pathway, an integrin-independent pathway for leukocyte 
adhesion has also been described. This pathway involves the interaction between the 
membrane-bound chemokine fractalkine (CX3CL1) on endothelium and chemokine receptors 
CX3CR1 on monocytes, T lymphocytes, NK cells, and dendritic cells (Fong et al. 1998). 
Both fractalkine and its receptor have been shown to be expressed in atherosclerotic lesions 
(Wong et al. 2002). To support the importance of endothelial-leukocyte interactions in 
atherosclerosis, various studies have shown that genetic deletion of E-selectin, P-selectin, 
ICAM-1, VCAM-1, or CX3CR1 leads to decreased lesion size in mouse models of 
atherosclerosis (Lesnik et al. 2003; Combadiere et al. 2003; Collins et al. 2000; Dong et al. 
1998). 
 
After the adherence of leukocytes to the endothelium, different chemotactic molecules are 
required for the transmigration of attached leukocytes through the endothelial lining to the 
arterial wall. Chemotactic molecules include complement components (C3a and C5a; see 
section Complement effectors), chemotactic cytokines (chemokines), and modified 
lipoproteins. Chemokines constitute a family of structurally related chemotactic cytokines, 
which are classified into subgroups (CC, CXC, C, CXXXC) based on the position of N-
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terminal cysteines, and they act through chemokine receptors on the target cells. A wide 
repertoire of both chemokines (e.g. MCP-1, RANTES, MIP-1α, MIP-1β, GRO-α, IL-8, IP-
10, fractalkine, eotaxin) and their receptors (e.g. CCR2, CCR3, CXCR2, CX3CR1) have been 
shown to be expressed in atherosclerotic lesions (reviewed by Weber et al. 2004; Sheikine & 
Hansson 2004), and it has also been shown that platelets interacting with endothelium may 
release chemokines and subsequently increase the recruitment of leukocytes to atherosclerotic 
plaque (Hundelshausen von et al. 2001). Interestingly, upregulation of chemokine expression 
is observed in response to various stimuli associated with atherosclerosis such as minimally 
modified LDL (Miller et al. 2005), complement activation products (Torzewski et al. 1996), 
and alterations in shear stress (Shyy et al. 1994). In addition, oxLDL can also directly induce 
chemotaxis of human monocytes (Quinn et al. 1987). The current assumption suggests that 
the recruitment of leukocytes requires cooperation of multiple chemotactic factors in distinct 
steps, but understanding of the recruitment pathways for individual leukocyte subclasses is 
limited. It is known, however, that the selective recruitment of mononuclear cells to the 
arterial wall during early atherogenesis results from the expression of VLA-4 in monocytes 
and T lymphocytes, but not in granulocytes. Similarly to adhesion molecules, genetic deletion 
or pharmacologic blockade of various chemokines or their receptors results in decreased 
atherosclerosis in mouse models (see Table 4), thus emphasizing the importance of these 
molecules in atherogenesis. 
 
 
2.3 Innate immunity in atherosclerosis 
 
The innate, non-adaptive immune system, which contains both cellular and soluble 
components, provides a fast (from minutes to hours) but blunt response, and serves as "first-
line" defense against infectious agents. Cells of the innate immune system are able to respond 
to pathogens via receptors called pattern recognition receptors (PRRs), which are able to 
recognize a restricted pattern of ligands called pathogen-associated molecular patterns 
(PAMP). These receptors are mainly expressed on cells of phagocytic origin, i.e. dendritic 
cells and macrophages. In addition to these receptors, the innate immune system comprises 
soluble factors such as the complement system, acute phase proteins, and cytokines, and also 
germ line-encoded antibodies, called natural antibodies (Cellular and Molecular Immunology, 
5th Edition, 2005 by Abbas et al.). All these may act together in the arterial intima to eliminate 
locally accumulated harmful agents, but by performing their physiologically meaningful 
functions, the activated innate immune system may also contribute to the pathogenesis of 
atherosclerosis (Fig. 2).  
 
2.3.1 Cells of innate immunity 
 
Various types of innate immune cells (macrophages, dendritic cells, NK cells, mast cells, 
neutrophils, B1 cells) have been suggested to play a role in atherogenesis. These cells exert 
their effects by cell-mediated cytotoxicity or by release of various cytokines, enzymes or 
antibodies, all of which are likely to have implications for the pathogenesis of atherosclerosis. 
In addition, dendritic cells and macrophages bridge innate and adaptive immunity by 
presenting antigens on their surface MHC class II molecules for recognition by cells of the 
adaptive immune system (lymphocytes).  
 
Macrophages 
Macrophages are the most abundant type of inflammatory cells in atherosclerotic lesions 
(approximately 80% of leukocytes), and they are present at all stages of atherosclerosis.




Fig. 2. Schematic representation of the players of the innate immune system in atherosclerotic lesions. 
Cells of innate immunity, notably monocytes, enter the arterial wall early in atherogenesis. In the arterial wall, 
monocyte-derived macrophages recognize foreign material by various pattern recognition receptors, which lead 
to their activation. In addition, other components of the innate immune system, e.g. acute phase reactant CRP, 
natural antibodies, and complement system, are present in the intima.  
 
 
Macrophages derive from blood monocytes, which under the influence of growth factors 
(monocyte colony-stimulating factor; M-CSF or granulocyte-macrophage colony-stimulating 
factor; GM-CSF) differentiate into tissue macrophages. These, in turn, are transformed into 
foam cells upon uptake of modified lipoproteins. Macrophages are important players of 
inflammation and the innate immune response in atherosclerosis, and they may contribute to 
various stages of atherogenesis by promoting local inflammatory reactions. Thus, 
macrophages produce pro-inflammatory cytokines (i.e. IL-1β, IL-6, IL-8, TNF-α), oxygen 
radicals, growth factors, leukotrienes, complement factors (reviewed by Østerud & Bjørklid 
2003), and enzymes capable of modifying lipoproteins (Hakala et al. 2003). In addition, 
macrophages may also promote plaque destabilization through production of proteolytic 
enzymes, e.g. matrix metalloproteinases (Galis et al. 1994). In addition, by serving as antigen-
presenting cells, macrophages may contribute to the activation of adaptive immune responses. 
The essential role of macrophages in atherogenesis is supported by the finding that apoE-/- 
mice deficient for M-CSF, which lack tissue macrophages, develop significantly less 
atherosclerosis than control mice (Smith et al. 1995).  
 
As players of the innate immune response, macrophages recognize foreign material by a 
variety of receptors that bind to target structures either indirectly via opsonic molecules or via 
direct interactions. The former process is based on the recognition of opsonic antibodies or 
complement products by macrophage Fcγ and complement receptors, respectively. In 
contrast, the latter process is based on the recognition of foreign structures by a repertoire of 
PRRs, notably scavenger receptors and Toll-like receptors (TLR). At least two of the 
scavenger receptors, scavenger receptor A (SR-A) and CD36, are of particular importance for 
the innate immune response in plaque. Thus, both receptors are involved in the uptake of 
modified lipoproteins and the transformation of macrophages into foam cells (reviewed by 
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Greaves & Gordon 2005). In addition, the uptake process via SR-A does route the antigen for 
presentation on MHC class II molecules and for further recognition by cells of the adaptive 
immune system (Nicoletti et al. 1999). In addition to modified LDL, scavenger receptors can 
recognize e.g. apoptotic cells and in pathogenic organisms (reviewed by Peiser et al. 2002). 
The role of Toll-like receptors, especially TLR4, has gained much attention in atherogenesis 
during recent years (reviewed by Tobias & Curtiss 2005). TLRs are a family of pattern 
recognition receptors with at least 10 members identified in mammals so far. The entire 
spectrum of these receptors has been detected in endothelial cells of the normal arterial wall, 
and at least the expression of TLR1, TLR2, and TLR4 is significantly increased in 
atherosclerotic plaques, in which they are mainly expressed by monocyte-macrophages and 
dendritic cells, but also by endothelial cells (Edfeldt et al. 2002; Xu et al. 2001). Interestingly, 
atherosclerotic lesions also contain various ligands that have been suggested to signal via 
TLRs, i.e. minimally modified LDL (Miller et al. 2003b), C. pneumoniae (Prebeck et al. 
2001), periodontal pathogens (Hajishengallis et al. 2002), and human HSP60 (Ohashi et al. 
2000). Ligation of TLRs leads to the activation of NF-κB- or IRF-3-responsive genes with 
subsequent synthesis of various pro-inflammatory cytokines, chemokines, adhesion molecules 
as well as co-stimulatory molecules (reviewed by Michelsen et al. 2004a), which can promote 
inflammation and activation of adaptive immune response in atherosclerotic lesions. 
Regarding the role of pattern recognition receptors in atherosclerosis, various animal studies 
have shown that genetic deletion of either scavenger receptors or TLR4 significantly 
decreases the extent of atherosclerosis (Suzuki et al. 1997; Febbraio et al. 2000; Björkbacka 
et al. 2004; Michelsen et al. 2004b). Furthermore, the TLR Asp299Gly polymorphism that 
attenuates receptor signaling is associated with decreased atherosclerosis and a reduced risk of 
acute coronary events in humans (Kiechl et al. 2002; Ameziane et al. 2003). However, some 
studies have failed to find such an association (Yang et al. 2003), and a recent report even 
suggested an increased risk of myocardial infarction in patients with Asp299Gly 
polymorphism (Edfeldt et al. 2004).  
 
Dendritic cells 
Dendritic cells are highly efficient antigen-presenting cells, which, in addition to expressing a 
high density of MHC class II molecules on their surface, also express a set of co-stimulatory 
molecules (e.g. B7-1 or B7-2) needed for the activation of naïve T cells. In addition to 
traditional T cells, dendritic cells can also present lipid antigens on CD1d for recognition by 
natural killer T cells (NKT cells)(Bobryshev & Lord 2002). A small number of dendritic cells 
have been shown to be present in the normal vessel wall in vascular-associated lymphoid 
tissue (VALT), especially in atherosclerosis-prone areas (Wick et al. 1997; Lord & 
Bobryshev 1999), and during the development of atherosclerotic lesion their number is further 
increased (Bobryshev & Lord 1995). In addition to entering the intima through luminal 
endothelium, it has also been suggested that dendritic cells may enter the intima via vasa 
vasorum (Bobryshev & Lord 1998) or differentiate from infiltrated monocytes (Randolph et 
al. 1998). It has also been shown that adhesion and endothelial transmigration of dendritic 
cells is increased by stimuli known to accelerate atherogenesis such as oxLDL (Weis et al. 
2002). Accumulating evidence indicates that dendritic cells are involved in antigen processing 
and presentation in vivo in atherosclerotic tissue. Thus, in atherosclerotic plaques, dendritic 
cells were observed in contact with T cells, which phenomenon was accompanied by the 
expression of ICAM-1 and VCAM-1, both of which are involved in dendritic cell-mediated T 
cell activation (Bobryshev & Lord 1998). Furthermore, similar colocalization was observed in 
the shoulder areas of vulnerable plaques, and in contrast to initial lesions, these dendritic cells 
exhibited a mature phenotype, indicating their functional activity, and suggesting that antigen 
presentation to and activation of T cells may affect the stability of plaque (Yilmaz et al. 
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2004). In addition, in the shoulder region of atherosclerotic lesions, CD1d-expressing 
dendritic cells were in direct contact with NKT cells, suggesting that presentation of lipid 
antigens also occurs in plaques (Bobryshev & Lord 2005a).  
 
Natural killer cells 
Natural killer cells (NK cells) are bone marrow-derived lymphocytes, which can function 
either by releasing cytoplasmic granules containing perforin and granzymes, which mediate 
direct cell-mediated cytotoxicity, or by producing pro-inflammatory cytokines, most 
importantly IFN-γ. A small number (approximately 0.1-0.5 % of the total T cell population) 
of NK cells have already been detected in the vessel wall in the early phases of 
atherosclerosis, and their number does not seem to increase during the progression of 
atherosclerosis (Millonig et al. 2002; Bobryshev & Lord 2005b). In contrast, NK cells have 
been widely detected in arterial aneurysms and even suggested to play a role in their 
formation (Seko et al. 1997). Despite the small number of NK cells in atherosclerotic lesions, 
elevated levels of circulating NK cells have correlated with severe atherosclerosis (Clerc & 
Rouz 1997). Several studies on experimental animals that have tried to shed light on the role 
of NK cells in atherogenesis have yielded controversial results. In LDLR-/- mice, perforin 
deficiency and Lystbeige mutation, both of which result in defective NK cell-mediated 
cytotoxicity, had different effects on atherogenesis; the former had no effect, whereas the 
latter increased atherosclerosis (Schiller et al. 2002). In contrast, a recent study demonstrated 
that a lack of functional NK cells results in significant reduction of lesion size in LDLR-/- 
mice (Whitman et al. 2004). Hence, it is possible that NK cells are involved in the 
pathogenesis of atherosclerosis, but the effect does not seem to depend on the cytolytic effects 
of NK cells.  
 
Mast cells 
Mast cells are cells of innate immunity that are traditionally known for their actions in allergic 
reactions. Upon activation, mast cells degranulate, i.e. release cytoplasmic secretory granules 
containing vasoactive substances such as histamine, proteolytic enzymes such as tryptase and 
chymase, inflammatory cytokines, growth factors, and heparin proteoglycans (Maurer et al. 
2003). In normal coronary intima, only a few mast cells are present in the subendothelial part. 
The number of mast cells increases during atherogenesis, and in advanced lesions they 
comprise 0.5-1% of the total intimal cell population (Kaartinen et al. 1994a). In advanced 
lesions, mast cells are mainly concentrated in the shoulder areas as part of the inflammatory 
infiltrate (Kaartinen et al. 1994a) and also occur around intimal neovessels (Kaartinen et al. 
1996). Atherosclerotic intima contains various substances that are known to activate mast 
cells, e.g. immune complexes (Ylä-Herttuala et al. 1994) and complement-derived 
anaphylatoxins (Vlaicu et al. 1985a). Interestingly, a very high proportion of mast cells (85%) 
in the shoulder area of an advanced atherosclerotic lesion are degranulated, reflecting the 
activation of these cells. This finding together with studies showing that mast cell 
degranulation and activation lead to the release of enzymes and cytokines that may weaken 
the structure of plaque (reviewed by Lindstedt & Kovanen 2004) suggests that mast cells may 
have a role in acute coronary events. Indeed, Kaartinen et al. detected an increased number of 
mast cells in the culprit lesions of patients with unstable angina (Kaartinen et al. 1998), and 
infiltrates of activated mast cells have been detected at the site of atheromatous erosion or 
rupture in myocardial infarction (Kovanen et al. 1995). During atherogenesis, mast cells may 
also interfere with lipid metabolism and thus promote accumulation of lipids both intra- and 
extracellularly in lesions, regulate T cell and macrophage responses, and promote endothelial 
dysfunction (reviewed by Vanderlaan & Reardon 2005). In contrast, mast cells may also exert 
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anti-atherogenic functions such as inhibition of collagen-induced platelet aggregation (Lassila 
et al. 1997) and prevent oxidation of LDL (Lindstedt 1993). To better define the significance 
of mast cells in atherogenesis, if any, animal studies with mast-cell-deficient mice and with 
mice with excessive numbers of mast cells are required.  
 
Neutrophils 
Neutrophils are the cells of the innate immune system that are characteristic of acute 
inflammation. They are able to phagocytose and destroy target structures and release reactive 
oxygen species, cytokines, antimicrobial peptides such as defensins, and various enzymes, 
some of which (e.g. MMP-8 and elastase) possess proteolytic activity. Neutrophils are rarely 
detected in stable human atherosclerotic plaques, but they are prevalent in the culprit lesions 
of patients with unstable angina as well as in the eroded and ruptured plaques of patients with 
myocardial infarction (Naruko et al. 2002). However, it is noteworthy, that since the life span 
of neutrophils in tissues is short (from a few hours to few days), even a small number of 
detected neutrophils in histological sections may reflect a more significant role for these cells 
in plaque in vivo. This is supported by a finding, which showed that leukocytes interacting 
with atherosclerotic endothelium are predominantly neutrophils (Eriksson et al. 2001). In 
addition, recent study by Sugano and coworkers showed that activated polymorphonuclear 
leukocytes from hypercholesterolemic patients produced increased amounts of superoxide, 
impaired endothelial function and showed increased adhesiveness to cultured endothelial cells 
(Sugano et al. 2005). Of interest, it has also been shown that upon intraluminal release of 
myeloperoxidase from neutrophils, this enzyme binds to endothelial cells and undergoes 
transcytosis to the subendothelial matrix (Baldus et al. 2001), where it can be involved in the 
oxidation of lipoproteins, for instance. Interestingly, it has been shown that neutrophils 
become activated as they traverse the coronary vascular bed in patients with unstable angina 
(Buffon et al. 2002). Moreover, a high number of circulating neutrophils has been reported to 
be an independent predictor of coronary heart disease and myocardial infarction (Madjid et al. 
2004).  
 
B1 cells and natural antibodies 
Natural antibodies are defined as antibodies that circulate in healthy individuals even in the 
absence of exogenous antigenic stimulation. They are produced by so-called B1 lymphocytes, 
are predominantly of IgM type, and contain highly-conserved sequences that recognize a 
variety of exogenous antigens as well as altered self structures. Thus, in addition to providing 
protection against invading pathogens, natural antibodies have been considered to have a 
“housekeeping” function in the removal of senescent and apoptotic cells and other self-
antigens, and thus to protect from autoimmunity (reviewed by Baumgarth et al. 2005). 
Indeed, the role of these antibodies might be emphasized in conditions that involve increased 
generation of non-self structures, as during atherogenesis.  
 
Natural antibodies were first linked to atherosclerosis when a panel of monoclonal IgM 
antibodies binding to oxLDL, more specifically the phosphoholine (PC) head group of 
oxidized phospholipids, were cloned from spleens of ApoE-/- mice (Palinski et al. 1996; 
Hörkkö et al. 1999). These antibodies (EO6 as a prototype) were able to stain both rabbit and 
human atherosclerotic tissue and recognize epitopes in human plasma LDL. In vitro studies 
showed that they also inhibited the uptake of oxLDL and apoptotic cells by macrophage 
scavenger receptors (Hörkkö et al. 1999; Chang et al. 1999). Further characterization of these 
IgM antibodies revealed that they were totally homologous (VH/VL-region) with the T15 
natural antibodies (Shaw et al. 2000) that are known to bind to phosphocholine molecules 
Literature Review 25 
present in the pneumococcal cell wall and confer to mice optimal protection against 
Streptococcus pneumoniae infection. Moreover, E06 and T15 were cross-reactive, since both 
bound to oxLDL as well as to the pneumococcal cell wall polysaccharide. The membranes of 
apoptotic cells were also shown to contain enriched amounts of PC-containing oxidized 
phospholipids that were recognized by natural antibodies (Chang et al. 2004). These findings 
suggested that IgM autoantibodies against oxidation-specific epitopes were actually natural 
antibodies present at birth and belonged to the innate immune response. Furthermore, these 
studies suggested that oxidation-specific neoepitopes represent PAMPs that are recognized by 
the components of the innate immune system, i.e. natural antibodies, scavenger receptors, and 
CRP. 
 
Natural antibodies have been suggested to play a protective role in atherogenesis. Thus, 
immunization of LDLR-/- mice with S. pneumoniae, which led to a significant increase in the 
plasma levels of IgM recognizing both oxLDL and pneumococcal cell wall polysaccharide 
and to expansion of T15 IgM-secreting B cells in the spleen, protected mice from 
atherosclerosis (Binder et al. 2003). In addition, immunization of LDLR-/- mice with MDA-
modified LDL led to reduced atherosclerosis, and this effect was associated with the Th2 type 
adaptive immune response, which also boosted the production of natural T15/E06 antibodies 
via production of IL-5. In addition, IL-5 deficiency was found to increase atherosclerosis in 
this mouse model, suggesting that the anti-atherogenic effects of immune activation against 
oxLDL could be partly mediated via a cytokine-induced increase in the production of 
T15/E06 natural antibodies (Binder et al. 2004).  
 
2.3.2 Acute-phase proteins 
 
Acute-phase reactants are plasma proteins, the level of which increase or decrease in response 
to infection, trauma or other inflammatory conditions, and whose concentration may also 
reflect the intensity of the process (Table 1). Acute-phase proteins are mainly produced by 
hepatocytes, but extrahepatic synthesis may also occur. As players of the innate immune 
response, acute-phase proteins may, for instance, enhance the activation of complement, 
promote the production of pro-inflammatory cytokines, assist in phagocytosis, and also 
increase the infiltration of leukocytes to the site of inflammation (reviewed by Gabay & 
Kushner 1999).  
 
In recent years, demonstration of a direct association between mildly elevated serum levels of 
various acute-phase proteins such as C-reactive protein (CRP), serum amyloid A, and 
fibrinogen and the risk of cardiovascular disease have been widely reported (reviewed by 
Ridker et al. 2004). It has been speculated that these mildly elevated levels of acute-phase 
proteins may reflect the presence of low-grade inflammation in the arterial tree or chronic 
infection associated with cardiovascular risk, or even that these proteins may be directly 
involved in the pathogenesis of atherosclerosis and its complications. Regardless of the 
underlying cause, they may provide the clinician with additional diagnostic and prognostic 
tools.  
 
The role and prognostic value of C-reactive protein in cardiovascular diseases has been under 
intensive research during recent years. CRP is an acute-phase protein, in which five identical 
subunits form a pentameric structure, and being pattern recognition receptor, it typically binds 
to the structures found on the surface of pathogens such as phosphocholine (reviewed by 
Black et al. 2004). Highly sensitive assays enable accurate determination of even very low 
plasma levels of CRP, and various prospective studies have shown that hsCRP is an 
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Table 1. Acute-phase proteins whose plasma concentrations increase during 
inflammatory process (Gabay & Kushner 1999)  
   
Complement system  Transport proteins 
C3  Ceruloplasmin 
C4  Haptoglobin 
C9   Hemopexin 
Factor B  Participants in inflammatory responses 
C1 inhibitor  Secretory phospholipase A2 
C4b-binding protein  Lipopolysaccharide-binding protein 
mannose-binding lectin  Interleukin-1-receptor antagonist 
Vitronectin  Granulocyte colony-stimulating factor 
Coagulation and fibrinolytic system  Others 
Fibrinogen  C-reactive protein 
Plasminogen  Serum amyloid A 
Tissue plasminogen activator  α1-Acid glycoprotein 
Urokinase  Fibronectin 
Protein S  Ferritin 
Plasminogen-activator inhibitor 1  Angiotensinogen 
Antiproteases   
α1-Protease inhibitor   
α1-Antichymotrypsin   
Pancreatic secretory trypsin inhibitor   
Inter-α-trypsin inhibitor   
     
 
 
independent risk factor of cardiovascular disease and myocardial infarction even in apparently 
healthy individuals (reviewed by Torres & Ridker 2003). Based on population samples, 
hsCRP levels of less than 1 mg/ml, 1-3 mg/ml, and more than 3 mg/ml should be interpreted 
as indicative of low, moderate, and high risk for cardiovascular disease, respectively. 
However, the usefulness of CRP as a novel additional marker of cardiovascular risk is still 
under debate, since a recent meta-analysis of previously published studies contradicted this 
view by showing that CRP was only a modest predictor of coronary events and added only 
marginally to the predictive value of the established risk factors (Danesh et al. 2004). 
However, the Centers for Disease Control and Prevention and the American Heart 
Association recently recommended that patients with an intermediate risk for developing 
CVD could benefit from the measurement of plasma CRP levels (Pearson et al. 2003). 
 
Whether CRP is merely a marker of inflammation or whether it could have an active role in 
atherogenesis is not known. However, the presence and expression of CRP in atherosclerotic 
plaques and the reported in vitro pro- and anti-inflammatory effects have suggested that CRP 
may affect atherogenesis. Indeed, the expression of CRP is increased in atherosclerotic 
plaques compared to healthy vessels (Yasojima et al. 2001b), and the plaques of patients with 
unstable angina showed significantly higher immunoreactivity to CRP than the plaques of 
patients with stable angina (Ishikawa et al. 2003). It has also been suggested that this local 
production of CRP could account for the elevated plasma levels, since the level of CRP was 
significantly higher in the cardiac vein than in the coronary arteries (Ishikawa et al. 2004). In 
addition, the translesional CRP gradient was greater in unstable than stable angina, suggesting 
that increased production of CRP by the lesional cells might reflect increased inflammation 
and instability of plaque (Inoue et al. 2005). Regarding the possible effects of CRP on plaque, 
both anti- and pro-atherogenic effects have been reported. Thus, CRP can be involved in the 
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clearance of modified self-structures by increasing their uptake either directly via Fcγ 
receptors or by activating the classical complement pathway with ensuing uptake of target 
structures via complement-derived opsonins (C1q and iC3b). Of the structures present in 
lesions, CRP has been shown to bind and increase the uptake of apoptotic cells and oxidized 
or enzymatically modified LDL (Chang et al. 2002; Gershov et al. 2000; Bhakdi et al. 1999; 
Taskinen et al. 2002). Furthermore, CRP has been shown to modulate the activation of the 
complement by enzymatically modified LDL in such a way that the detrimental end product 
C5b-9 is not generated (Bhakdi et al. 2004). In contrast, CRP also induces the expression of 
adhesion molecules, chemokines, and endothelin-1 by endothelial cells, is chemotactic for 
monocytes, and induces SMC apoptosis (reviewed by Paul et al. 2005). However, it is 
noteworthy that at least cell culture studies on the effects of CRP on intimal cell types should 
be interpreted with caution, since the results may be affected by endotoxin or azide 
contamination of commercial CRP preparations (Taylor et al. 2005). Recent studies with 
experimental animals have provided ambiguos findings about the role of CRP in 
atherogenesis. Thus, the study by Paul et al. showed that transgenic expression of human CRP 
accelerates the development of atherosclerosis in male but not female apoE-/- mice (Paul et al. 
2004), whereas three other studies failed to reveal any such effect for either human or rabbit 
CRP transgene in apoE-/- (Hirschfield et al. 2005; Reifenberg et al. 2005) and apoliporotein 
E*3 Leiden (Trion et al. 2005) mice. These conflicting results may be explained by the fact 
that, in the study of Paul et al., the CRP concentrations were extraordinarily high compared to 
the other studies using the same transgenic strain, possibly reflecting a concurrent 
inflammatory process. In addition, it seemed that, in apoE-/- mice, CRP was not able to 
activate the complement system, which is one of its primary functions, and these results 
should hence be interpreted and extrapolated to humans with caution (Reifenberg et al. 2005).  
 
2.3.3 Complement system 
 
Introduction 
The father of the complement is Dr. Jules Bordet, who in the late 19th century described a 
heat-labile activity in serum that could complement the ability of a specific antibody to cause 
lysis of bacteria. Today this heat-labile activity is known to comprise dozens of serum 
proteins and is known as the complement system. Traditionally, complement is regarded to be 
part of the innate immunity, although it has recently also become regarded as a key modulator 
of adaptive immunity. Complement is known to function both in the defence against microbes 
and in the clean-up of tissues, e.g. in the disposal of immune complexes and apoptotic cells. 
To exert its biological activities, the complement system needs to be activated, after which it 
generates a variety of functional molecules, i.e. opsonins, anaphylatoxins, and terminal 
membrane attack complex, all of which act separately or together to destroy the target 
structure (Cellular and Molecular Immunology, 5th Edition, 2005 by Abbas et al.) In addition, 
as a bridge between innate and adaptive immunity, the complement system modulates both B 
and T cell responses to antigens through the complement receptors and regulators present on 
the lymphocyte surface (reviewed by Morgan et al. 2005).  
 
The complement system consists of approximately 30 proteins, including complement 
proteins and fluid-phase and membrane-bound regulators. A number of complement proteins 
are proteolytic enzymes that also in themselves become activated by proteolytic cleavage. 
Thus, a component of the system often serves as a substrate of a previous component and 
then, once activated, acts as an enzyme to activate the subsequent component. This pattern of 
sequential activation produces an expanding cascade of activity, which means that the 
activation of a single molecule will lead to thousands of molecules being generated in the 
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following steps. Thus, many regulatory mechanisms are needed to prevent uncontrolled 
complement activation and tissue damage.  
 
The intitial finding of complement activation products in atherosclerotic lesions suggested 
that this mechanism of innate immunity is functional during atherogenesis. Since then, 
various structures capable of activation have been demonstrated in atherosclerotic lesions, and 
the effects of complement activation products on lesional cells have been widely investigated 




Depending on the nature of the activator, three different activation pathways, namely the 
classical, alternative, and lectin pathways, have been described. Each pathway utilizes 
different proteins to recognize the activators and to initiate the cascade. However, all three 
pathways converge at the level of C3 and share a common terminal pathway. In general, the 
components of the classical pathway and the terminal pathway are designated with the letter C 
followed by a number such as C4, whereas the components of the alternative pathway are 
called “factors” and are identified with a single letter such as factor D. The split products of 
the components that are generated by proteolytic cleavage are distinguished from their 
precursors by suffix letters such as C4b. The complement activation is reviewed in Cellular 
and Molecular Immunology, 5th Edition, 2005 by Abbas et al. A schematic view of 
complement activation and its regulators is presented in Fig. 3. 
 
The classical complement pathway is primarily activated by antigen-bound IgG or IgM 
molecules, but CRP (Siegel et al. 1974), nucleic acids (Jiang et al. 1992), or apoptotic cells 
(Nauta et al. 2002b) can also initiate its activation. The activation involves recognition and 
binding of C1q to the activators with subsequent proteolytic activation of C1q-associated C1r 
and C1s. C1s is a serine protease that cleaves C4 with ensuing release of small peptide C4a 
and generation of larger C4b, which is capable of binding to nearby surfaces containing 
hydroxyl or amino groups. Surface-bound C4b binds C2, which can also become cleaved by 
C1s. While the generated C2a is released, C2b remains bound to C4b, thus forming the 
classical pathway C3 convertase C4b2b. This convertase, in turn, is cabable of cleaving C3 to 
C3a and C3b, and when C3b binds to the C4b2b complex, a functional C5 convertase is 
formed.  
 
The alternative complement pathway is continuously undergoing low-grade spontaneous 
activation to generate C3b i.e. “C3 tickover”. The generated C3b has the potential to bind to 
amino and hydroxyl groups on the nearby surfaces. If C3b binds to nonactivating surfaces, i.e. 
host cells, is rapidly inactivated by factor H and factor I, whereas C3b bound to activating 
surfaces that do not express or lack complement inhibitors, i.e. pathogens or other foreign 
surfaces, persists. The membrane-fixed C3b next binds factor B, which then becomes cleaved 
by factor D to Bb. The C3bBb complex is alternative pathway C3 convertase, which is 
stabilized by properdin (C3bBbP), and which is able to to cleave even more C3 molecules. 
This C3b-Bb-factor D circle is called “amplification loop”, and it is necessary for efficient 
complement activation. The amplification loop also attends the augmentation of the 
complement activation initiated by the classical pathway (Müller-Eberhard 1988). An 
alternative pathway C5 convertase is formed when C3b binds to C3bBb (C3b2Bb). 
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Figure 3. Schematic representation of the complement system and its regulators. Opsonins generated during 
complement activation are colored brown and anaphylatoxins yellow. Complement regulators are colored blue. 
Adapted from Oksjoki et al. (2003).  
 
 
Finally, the lectin pathway of activation involves the binding of mannose-binding lectin 
(MBL) or ficolins, which are typical pattern recognition receptors, to carbohydrate groups on 
the surface of bacterial cells. This recognition is followed by the activation of associated 
enzymes, MBL-associated serine proteases (MASPs), which can cleave C4 and C2 with 
subsequent activation of the classical complement pathway (reviewed by Fujita et al. 2004).  
Regardless of the initial pathway of activation, all pathways converge with the activation of 
the central C3 component. If the complement cascade is not regulated at this level, it proceeds 
to the activation of the terminal common pathway. In this pathway, C5 is cleaved into C5a 
and C5b by either the classical or alternative pathway C5 convertases, C4b2b3b and C3b2Bb, 
respectively. The ensuing sequential binding of C6, C7 and C8 to the emerging C5b678 
complex does not require proteolytic cleavage, and the resulting complex guides the 
polymerization of as many as 10-16 molecules of C9 into a tube inserted into the lipid bilayer 
of the plasma membrane. The resulting pore-forming structure (C5b-9) is called “membrane-
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attack complex”, and it allows the passage of ions and small molecules into the cell with 
ensuing cell lysis  
Since complement activation proceeds as an expanding cascade of activity, this easily 
explosive potential needs to be kept under strict control to avoid harmful tissue destruction. 
The regulatory mechanisms of the complement system are presented in the section 
Complement regulators in atherosclerotic lesions. 
Complement activation products in atherosclerotic lesions 
There is powerful evidence to indicate that the complement system is activated in human 
atherosclerotic, but not non-atherosclerotic, arterial wall. As early as 1979, Hollander and 
coworkers isolated complement C3 from the arterial wall and observed much higher C3 levels 
in atherosclerotic lesions than in normal vessel wall (Hollander et al. 1979). Subsequently, 
inactivation products of C3, more specifically C3c and C3dg, were also found in extracts of 
atherosclerotic lesions, suggesting that C3 had undergone proteolytic cleavage and activation 
(Seifert et al. 1991). Similarly, immunohistochemical stainings have demonstrated deposits of 
C3c as thin streaks and homogenous bands in the superficial intima (Vlaicu et al. 1985a), and 
in another study, C3 was also found in endothelial cells at sites of injury and in subendothelial 
intima (Hansson et al. 1984). Quantative determinations of complement components in 
atherosclerotic lesions have revealed that the complement proteins C1q, C3, C3a, C3c, C4, 
and C9 presented higher intima/serum ratios than the other serum proteins studied (albumin, 
transferrin, α1-antitrypsin, α2-macroglobulin, fibrinogen), suggesting preferential retention of 
these complement proteins in the intima (Vlaicu et al. 1985c). Furthermore, the observed 
increase in the intima/serum ratio may also partly result from increased local production of 
complement proteins in atherosclerotic lesions (Yasojima et al. 2001a; Yasojima et al. 
2001b).  
 
In addition to individual complement components, the terminal membrane-attack complex 
(MAC, C5b-9) has also been detected in atherosclerotic lesions. Similarly to complement 
components, C5b-9 is not present in normal arterial wall. However, as shown in cholesterol-
fed rabbits, deposition of C5b-9 in the intima is an early event in atherogenesis, since it 
correlates temporally with cholesterol accumulation in the subendothelium and occurs before 
monocyte infiltration and foam cell formation (Seifert et al. 1989). Indeed, C5b-9 has been 
demonstrated in atherosclerotic lesions at all stages (Torzewski et al. 1997; Vlaicu et al. 
1985a), and analysis of lesional extracts revealed that the amount of C5b-9 correlates with 
lesion severity (Niculescu et al. 1987a). In addition, the majority of lesional C5b-9 is in a 
membraneous, cytolytic form, suggesting that it has been formed in situ in the lesions (Seifert 
et al. 1990). Immunohistochemical analyses have shown that, throughout lesion development, 
C5b-9 appears as granular deposits in the deep parts of the intima adjacent to the media and 
occasionally also in the inner third of the media (Torzewski et al. 1997; Niculescu et al. 
1987c). In the deep area, C5b-9 has been shown to colocalize with smooth muscle cell α-actin 
(Torzewski et al. 1997), CRP (Torzewski et al. 1998a), apoptotic cells (Niculescu et al. 2004) 
as well as modified lipids (Torzewski et al. 1998b). In line with these results, smooth muscle 
cells have been suggested to be the initial target of the complement attack, since these cells 
often lack an important membrane-bound complement inhibitor protectin (CD59) (Seifert et 
al. 1992), whereas CRP, apoptotic cells and modified lipids represent potential activators of 
the complement system in the lesions (see the section Complement activators in 
atherosclerotic lesions).  
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Complement activators in atherosclerotic lesions 
During atherogenesis, various structures that are capable of activating complement are either 
generated or deposited in the arterial wall. These include immune complexes containing IgM 
or IgG, pentraxins CRP and PTX3, and also modified lipids. In addition, other potential 
complement activators in the lesions include cholesterol crystals (Seifert & Kazatchkine 
1987), apoptotic cells (Mevorach et al. 1998), and cell debris (Pinckard et al. 1975).  
 
Immune complexes are traditionally regarded as activators of the classical complement 
pathway, but they have recently also been shown to increase the activation of the alternative 
complement pathway by stabilizing C3 convertase (Ji et al. 2002). Since the arterial wall is 
known to contain various (auto)antigens, against which a humoral immune response is 
generated, it is likely that atherosclerotic lesions contain at least some immune complexes. 
Indeed, both of the immunoglobulins G and M have been extracted and 
immunohistochemically detected in atherosclerotic arterial intima, and part of the extracted 
IgG was found to be tissue-bound, suggesting that it was in the form of immune complexes 
(Hollander et al. 1979; Vlaicu et al. 1985b). In addition, lipoprotein-containing immune 
complexes have been isolated from atherosclerotic lesions (Ylä-Herttuala et al. 1994), and 
very recently autoimmune oxLDL-IgG immune complexes were verified to be able to activate 
the classical complement pathway (Saad et al. 2006).  
 
CRP is a pentameric acute-phase protein that has been shown to activate the classical 
complement pathway both in vitro (Siegel et al. 1974) and in vivo (Wolbink et al. 1996). 
However, in contrast to complement activation by other classical pathway activators, CRP-
initiated activation inefficiently generates C5b-9, which is likely to result from the recruitment 
of complement inhibitor factor H by CRP (Jarva et al. 1999). In contrast, CRP-initiated 
activation efficiently coats target structures with complement-derived opsonins. In regard to 
atherogenesis, CRP as well as another complement-activating pentraxin, pentraxin 3 (PTX3), 
have been detected in atherosclerotic lesions (Rolph et al. 2002). In the arterial wall, CRP 
binds to various ligands such as enzymatically modified lipids and apoptotic cells, activates 
the classical complement pathway, and may thus promote the uptake of target structures by 
phagocytes via either FcγRs or complement receptors (Bhakdi et al. 1999; Gershov et al. 
2000). Regarding complement activation, monomeric, modified CRP is also of interest. This 
modified form CRP has been shown to be present in the arterial wall and it has suggested to 
be produced from native, pentameric CRP due to the low pH at the sites of inflammation, for 
instance (Diehl et al. 2000). Regarding complement activation, a recent study showed that 
fluid-phase mCRP inhibited complement activation, possibly by binding to the collagen-like 
region of C1q and thus preventing its binding to other complement activators. Interestingly, 
however, when mCRP was immobilized to modified lipoproteins, for instance, it activated the 
early classical complement pathway (Ji et al. 2006).  
 
During atherogenesis, intimal lipoproteins undergo modifications, which allow them to 
activate the complement system. Indeed, lipids isolated from human atherosclerotic lesions 
are able to activate the alternative complement pathway (Seifert et al. 1990), and lipids 
complexed with C5b-9 have been extracted from the intima (Seifert et al. 1990). In addition, 
enzymatic modification of LDL by trypsin, cholesterol esterase, and neuraminidase converts 
LDL to particles with properties akin to those extracted from atherosclerotic lesions, including 
the capacity to activate the complement to completion via the alternative pathway (Bhakdi et 
al. 1995). However, at low concentrations of E-LDL, CRP bound to E-LDL can activate the 
classical complement pathway and, likely via recruitment of factor H, stops the activation 
before the generation of C5b-9 (Bhakdi et al. 1999; Bhakdi et al. 2004). Accordingly, in the 
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very early stages of atherosclerosis, E-LDL showed only little colocalization with C5b-9 
(Bhakdi et al. 2004), whereas colocalization was obvious in more advanced lesions 
(Torzewski et al. 1998b).  
 
Complement effectors 
There are three main mechanisms through which complement exerts its effects on 
inflammation and the immune response. First, complement activation generates large numbers 
of split products of complement proteins and their inactivation products (such as C4b, C3b 
and iC3b), which can bind covalently to target structures and promote their removal by 
phagocytes bearing receptors for complement proteins. Second, small fragments called 
anaphylatoxins (C4a, C3a, C5a) are generated in the cleavage of complement proteins. These 
peptides are chemokines and can also activate various cells. Third, the terminal membrane-
attack complex (C5b-9) can form a pore-like structure on the bacterial/cell surface and thus 
destroy it, but it is important to note that, at non-lethal “sublytic” concentrations, C5b-9 does 
not kill the target cells, but rather elicits many pro-inflammatory effects in them.   
 
Opsonins 
One of the most important functions of complement is to facilitate the uptake of foreign 
particles and pathogens by phagocytic cells. In addition, the same mechanisms act in the 
clean-up of tissues from, for instance, cell debris. This process involves the coating of target 
particles by opsonins such as split products of C4 and C3, of which C3b and iC3b are the 
most important. The receptor for C3b and C4b is CR1 (CD35), and the receptors for iC3b are 
CR3 (CD11b/CD18) and CR4 (CD11c/CD18). In atherosclerotic lesions, CR1 and CR3 are 
both expressed at least by macrophages (Seifert & Hansson 1989; Saito et al. 1992). In 
addition to cell debris, opsonization plays a role in the clearance of apoptotic cells. Apoptotic 
cells can activate both the classical and alternative complement pathways resulting in the 
deposition of iC3b on their surfaces, followed by phagocytosis of dying cells via CR3 with a 
minimal inflammatory reaction (Mevorach et al. 1998; Gershov et al. 2000). In addition, 
opsonization of antigens can also modulate the adaptive immune response against them. Thus, 
it was recently found that opsonization with C3d markedly increased, and opsonization with 
C3b decreased the immunogenity of various antigens, presumably acting via complement 
receptors present on B lymphocytes, dendritic cells, and T cells (reviewed by Morgan et al. 
2005). Furthermore, a recent paper suggested that the formation of C3b and other C3-derived 
molecules could at least partly explain the antiatherogenic effect of intravenous 
immunoglobulin injections in LDLR-/- mice (Persson et al. 2005). 
 
Anaphylatoxins 
During complement activation, the proteolytic cleavage of C4, C3 and C5 results in the 
generation of short-lived anaphylatoxins C4a, C3a and C5a, respectively. Of these, C4a has 
been shown to possess only weak activity, whereas C3a and C5a are potent inflammatory 
mediators. Once generated, C3a and C5a exert their biological effects through specific seven 
transmembrane domain G-protein-coupled receptors, which have been found to be expressed 
in myeloid cells such as monocytes, neutrophils and mast cells (Martin et al. 1997; Zwirner et 
al. 1999; Fureder et al. 1995) as well as in various non-myeloid cells such as neurons of the 
central nervous system (Davoust et al. 1999; Gasque et al. 1998; Gasque et al. 1997), tubular 
cells in the kidneys (Braun et al. 2004; Zahedi et al. 2000) and endothelium and smooth 
muscle cells in the lungs (Fregonese et al. 2005). The expression of the two anaphylatoxin 
receptors (C3aR and C5aR) is greatly increased during inflammation, as has been 
demonstrated in the inflamed human central nervous system (Gasque et al. 1998). 
Literature Review 33 
Both anaphylatoxins are potent mediators of inflammation, but they also exert 
immunomodulatory effects on both innate and adaptive immune response. Thus, C3a and C5a 
are chemotactic for monocytes (Arend et al. 1989; Zwirner et al. 1998b) and mast cells 
(Hartmann et al. 1997), cause respiratory burst (Fischer et al. 1995) and secretion of 
proinflammatory cytokines from macrophages (Takabayashi et al. 1998; Takabayashi et al. 
1996; Goodman et al. 1982; Ember et al. 1994), and trigger mast cell degranulation 
(Schulman et al. 1988; el-Lati et al. 1994). Furthermore, C5a has been shown to cause 
upregulation of adhesion molecules on endothelial cells (Foreman et al. 1996; Albrecht et al. 
2004), and both C3a and C5a have been shown to induce expression of proinflammatory 
cytokines in cultured human umbilical vein endothelial cells (Albrecht et al. 2004; Monsinjon 
et al. 2003). In addition, activation of mast cells and macrophages through C5aR has been 
shown to regulate the expression of Fcγ receptors and thus to play a causal role in 
experimental immune complex-induced disease (Bozic et al. 1996; Hopken et al. 1997; 
Godau et al. 2004; Baumann et al. 2001; Shushakova et al. 2002). Although C3a and C5a 
share many similar functions, they seem to have to some extent opposing effects on the 
regulation of adaptive immunity. Thus, C5a is chemoattractant for T lymphocytes (Nataf et al. 
1999; Tsuji et al. 2000), potentiates T cell proliferation (Morgan et al. 1983), and drives the 
Th1-type immune response that has been suggested to be proatherogenic. In contrast, C3a has 
been shown to mediate immunosuppressive effects (Morgan et al. 1982) and also to drive the 
Th2-type immune response (Hawlisch et al. 2004) that has been suggested to promote 
antiatherogenic effects.  
 
Membrane-attack complex 
Activation of the terminal complement pathway, which leads to the assembly of the 
membrane-attack complex C5b-9 and forms functional pores in the cell membrane, may result 
in cell swelling and subsequent cell lysis. A single functional channel is sufficient to cause 
lysis of an erythrocyte, but nucleated cells are more resistant, since at low “sublytic” 
concentration of C5b-9, they can escape lysis by exocytosing and endocytosing C5b-9. 
However, these non-lethal “sublytic” concentrations of C5b-9 may affect cell function and 
mediate signaling via various pathways, e.g. by inducing the influx of calcium into cell 
(Seeger et al. 1986). Moreover, C5b-9 directly activates signaling pathways that involve 
NFκB and cdk4/cdk2, which are known to activate a set of pro-inflammatory genes, and DNA 
synthesis and cell proliferation, respectively (Kilgore et al. 1997; Niculescu & Rus 1999). 
Accordingly, in vitro studies have demonstrated that sublytic concentrations of C5b-9 have 
many effects that may increase inflammation and also affect the stability of atherosclerotic 
lesion. Thus, sublytic concentrations of C5b-9 upregulate the expression of the adhesion 
molecules ICAM-1 and VCAM-1 and E-selectin by endothelial cells (Tedesco et al. 1997; 
Kilgore et al. 1995). In addition, sublytic concentration of C5b-9 induce secretion of the 
growth factors bFGF and PDGF (Benzaquen et al. 1994) and the chemotactic molecules 
interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) from endothelial cells 
(Kilgore et al. 1997). Furthermore, the assembly of C5b-9 on smooth muscle cells leads to the 
release of monocyte chemotactic protein-1 (Torzewski et al. 1996) and induces SMC 
proliferation (Niculescu et al. 1999). C5b-9 may also protect vascular smooth muscle cells 
from apoptosis by inducing secretion of insulin-like growth factor-1 (Zwaka et al. 2003). 
However, at higher concentrations, C5b-9 has also been shown to induce caspase activation 
and apoptosis (Nauta et al. 2002a), and it has been shown to colocalize with markers of 
apoptosis in atherosclerotic lesions (Niculescu et al. 2004), suggesting that C5b-9 may be 
involved in the induction of apoptosis of vascular cells.  
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Complement regulators in atherosclerotic lesions 
The complement system is regulated at almost all the levels of activation by both soluble and 
membrane-bound regulators. This is of great importance, since it prevents complement from 
attacking host cells and protects the tissues of the host from being damaged by uncontrolled 
complement activation. Various complement regulatory proteins have also been shown to be 
present in atherosclerotic lesions (Seifert & Hansson 1989). In addition, there is evidence 
that complement regulatory proteins are actively expressed in arteries, and their expression 
level is similar in both normal and atherosclerotic vessel wall (Yasojima et al. 2001a). 
Complement regulators are listed in Table 2, and the sites of their action are shown in Fig. 3. 
Table 2 also lists the studies that have demonstrated the presence of complement regulators 
in atherosclerotic lesions.   
 
Table 2. Complement regulators, their function, and their presence in atherosclerotic 
lesions 
Regulatory protein General function 
 
Demonstrated to be present in 
atherosclerotic lesions by: 
Soluble regulators  
C1-inhibitor Binds and inactivates C1r and C1s Seifert & Hansson 1989 
C4b-binding protein Accelerates decay and inhibits CP  Kimoto et al. 1996 
 C3 convertase, cofactor for factor I  
Factor H Accelerates decay and inhibits AP  Seifert & Hansson 1989 
 C3 convertase, cofactor for factor I  
Factor I Cleaves and inactivates C3b and C4b 
in the presence of cofactor  
Properdin Stabilizes AP C3 convertase Seifert & Hansson 1989 
S protein Prevents assembly of C5b-9 Niculescu et al. 1987b 
Clusterin Prevents assembly of C5b-9 Ishikawa et al. 1998 
Membrane-bound regulators  
DAF (CD55) Accelerates decay of AP and CP Seifert & Hansson 1989 
 C3 and C5 convertases  
MCP (CD46) Cofactor for factor I  
CR1 (CD35) Accelerates decay of AP and CP  Saito et al. 1992 
 
C3 and C5 convertases, cofactor for 
factor I  
Protectin (CD59) Prevents assembly of C5b-9  Seifert et al. 1992 
   
AP, alternative pathway; CP, classical pathway; DAF, decay-accelerating factor; MCP, membrane cofactor 
protein; CR1, complement receptor 1 
 
 
The immunohistochemical studies showing the presence of regulators in atherosclerotic 
lesions failed to provide evidence for the regulatory activity of these components in 
complement activation in lesions. Thus, Seifert and coworkers were unable to demonstrate 
any obvious spatial relation between C5b-9 complexes and any of the complement regulatory 
proteins studied (CR1, C1-INH, factor H, properdin, DAF) (Seifert & Hansson 1989). 
Similarly, terminal C5b-9 complexes were present in areas with and without CD59 (Seifert et 
al. 1992) and DAF (Niculescu et al. 1990). However, the partial colocalization of S-
protein/vitronectin and C5b-9 suggested that a fraction of C5b-9 may have been 
inactivated/solubilized by S-protein/vitronectin (Niculescu et al. 1987c). As this thesis 
concentrates on the role C4b-binding protein and factor H in the regulation of complement 
Literature Review 35 
activation in atherosclerotic lesions, only these two regulators will be described in greater 
detail.  
 
C4b-binding protein (C4bp) is a key inhibitory molecule for the classical and lectin pathways 
of complement. The average plasma concentration of C4bp is ~260 nM (150 µg/ml) (Griffin 
et al. 1992), but since it is an acute-phase protein, its levels may increase up to 4-fold during 
inflammation, infection, and tissue damage (Saeki et al. 1989). C4bp is a 500 kDa molecule, 
which consists of six or seven α-chains and one β-chain. The α-chains are built up of eight 
short consensus repeat (SCR) domains, and the β-chain contains three such SCR modules 
(Hillarp & Dahlbäck 1988). The chains are linked together by disulfide bridges at their C-
terminal domains, and C4bp therefore appears as a spider-like structure in electron 
microscopy (Dahlbäck et al. 1983). C4bp inhibits the classical complement pathway by 
preventing the assembly and accelerating the decay of the C4b2a complex, and acting as a 
cofactor for factor I in the cleavage and inactivation of C4b (Gigli et al. 1979). The C4b-
binding site has been localized to the SCRs 1–3 of the α-chains of C4bp, and the same area 
also harbors the binding sites for heparin (Blom et al. 2001). The majority of C4bp circulates 
in complex with protein S, which is part of the anticoagulant system. Upon the formation of 
this complex, the anticoagulant activity of protein S is lost (Dahlbäck 1986), but the 
complement inhibitory properties of C4bp remain unaffected. In atherosclerotic aortas, C4bp 
has been found to locate diffusely in the intima, with more intensive staining in foam cells 
and the necrotic core (Kimoto et al. 1996). In addition, the intimal cells of both normal and 
atherosclerotic aortic wall were found to express C4bp (Yasojima et al. 2001a). 
 
Factor H is a key inhibitor of activation by the alternative pathway. Factor H is a single-chain 
glycoprotein (155 kDa) that is present in plasma at concentrations ranging from about 100 
µg/ml to about 600 µg/ml. Factor H is composed of 20 repetitive short consensus repeat 
domains (SCR) (Zipfel et al. 1999), which form a string-like structure. Factor H binds C3b 
and thus inhibits the assembly and promotes the decay of alternative pathway C3 convertase 
and further acts as a co-factor for factor I in the proteolytic cleavage of C3b (Whaley & 
Ruddy 1976; Weiler et al. 1976; Pangburn et al. 1977). Factor H regulates complement both 
in the fluid phase and on cellular surfaces, but the inactivation of surface-bound C3b by factor 
H is dependent on the presence of sialic acids or other polyanionic molecules on the surfaces 
of intact human cells (Fearon 1978). In addition to containing three distinct binding sites for 
C3b (Jokiranta et al. 2000), factor H also contains three heparin-binding sites (Blackmore et 
al. 1996; Blackmore et al. 1998; Pangburn et al. 1991). Previous studies detected factor H in 
atherosclerotic but not in non-atherosclerotic intimas, where it was located on connective-
tissue fibers in a granular, thread-like pattern (Seifert & Hansson 1989).  
 
Complement-deficient animals and atherosclerosis 
Experimental studies with complement-deficient animals have been made to elucidate the role 
of the complement system in atherogenesis, but the results have been controversial. As early 
as 1970, Geertinger and Sørensen showed that the formation of vitamin D-induced 
atherosclerotic-like lesions in rats was diminished when the complement system was depleted 
by using zymosan (Geertinger & Sørensen 1970). Later, the same group observed that an 
atherogenic diet induced less atherosclerosis in rabbits deficient in C6 than in controls with a 
fully functional complement system (Geertinger & Sørensen H 1977). These results were 
confirmed by a similar experimental setup twenty years later (Schmiedt et al. 1998). 
Similarly, an anticomplement agent K-76 COONa was found to suppress the development of 
atherosclerosis in cholesterol-fed rabbits without affecting serum cholesterol levels (Saito et 
Literature Review 36 
al. 1990). In addition, injections of a complement inhibitor, vaccinia virus complement 
control protein, led to significantly reduced lesion size in C57Bl/6 mice fed high-fat diet 
(Thorbjornsdottir et al. 2005) However, contrasting results were obtained in C5 deficient 
apoE-/- mice, which showed a similar extent of atherosclerotic lesions compared to 
complement-competent control mice (Patel et al. 2001). More recently, two studies 
investigated the role of C3 deficiency in atherosclerosis. A study by Buono and coworkers 
showed that, in LDLR-/- mice, C3 deficiency leads to larger lipid-positive areas in en face 
preparations of descending aorta, but not in the aortic root. In addition, lesions contained 
increased numbers of macrophages but decreased quantities of collagen and smooth muscle 
cells, suggesting that maturation was impared in the absence of C3 (Buono et al. 2002). 
Similarly, the study by Persson and coworkers reported increased atherosclerosis in the 
descending aortas of C3 deficient LDLR-/-apoE-/- mice, while no qualitative differences were 
observed between the lesions in C3 deficient and complement-competent control mice 
(Persson et al. 2004). Of interest, in the latter study C3 deficient mice had a more atherogenic 
lipid profile than control mice, which probably resulted from defective triglyceride synthesis 
by adipocytes because of the absence of C3-derived acylation-stimulating protein (ASP). In 
contrast, deficiency of factor B affected neither lipid levels nor lesion size (Persson et al. 
2004). These results, together with a recent study demonstrating that C3 deficiency abolishes 
the antiatherogenic effect of intravenous immunoglobulin treatment (Persson et al. 2005), 
suggest that the activation of the early complement pathway with generation of opsonins may 




2.4 Adaptive immunity in atherosclerosis 
 
The adaptive immune response is based on the antigen-specific reactions proceeding through 
T and B lymphocytes. In contrast to innate immunity, this type of response is slow and may 
take days to weeks to develop. However, the adaptive immune response has a memory, and 
subsequent exposure to the antigen leads to a more vigorous and rapid response, which 
reflects the pre-existence of a clonally expanded population of antigen-specific lymphocytes. 
The capacity of adaptive immunity to respond specifically to a wide variety of different 
antigens relies on the somatic rearrangement processes in progenitor cells, which can 
potentially results in the generation of approximately 1016 different T cell receptors (TCR) and 
1011 different immunoglobulin molecules, which are used as B cell receptors. However, the 
actual number of these receptors in individual is only approximately 107-1011 (Cellular and 
Molecular Immunology, 5th Edition, 2005 by Abbas et al.). T cells recognize the complex of 
antigenic peptide in association with self MHC molecules and require additional co-
stimulatory signals to become activated and to exert their effects. Cytotoxic CD8+ 
lymphocytes act directly by attacking cells that present their specific antigen on MHC class I 
molecules, whereas helper CD4+ T cells recognize antigens on MHC class II molecules and 
provide help for other immune cells either by producing cytokines or by direct cell-cell 
interactions. In contrast, B cells can recognize their specific antigens directly with their 
surface-bound IgM molecules, and upon further help from T cells, they start producing 
antibodies of similar specificity. Atherosclerotic lesions have been shown to contain cells of 
adaptive immunity and antibodies as well as cytokines produced predominantly by these cells, 
and animal studies have suggested that adaptive immunity plays a role in atherogenesis (see 
the section Effects of immune system in atherogenesis). The players of adaptive immunity in 
atherosclerotic lesions are summarized in Figure 4. 
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Figure 4. Schematic representation of the players of the adaptive immune system in atherosclerotic 
lesions. Antigen-presenting cells, notably macrophages and dendritic cells, present antigens on the surface MHC 
class II molecules for recognition by cells of adaptive immunity, i.e. lymphocytes. As a result, both cellular and 




2.4.1 T lymphocytes 
 
T lymphocytes enter the arterial wall early in atherogenesis, and these cells can therefore be 
observed in atherosclerotic lesions at all stages of lesion development (Jonasson et al. 1986; 
van der Wal et al. 1989). In advanced atherosclerotic lesions, about 5 to 20% of cells are T 
lymphocytes (Jonasson et al. 1986; Hansson et al. 1989), of which the majority are CD4+ 
helper T cells bearing αβ T cell receptor. A substantial proportion of T cells also bear markers 
such as IL-2 receptor, MHC class II, CD45RO, or very late antigen-1 (VLA-1), suggesting 
that these cells are in an activated state (Hansson et al. 1989; van der Wal et al. 1989; Stemme 
et al. 1992) and may have become stimulated by local antigens. Indeed, upon encounter with 
and recognition of an antigen, T cells may become activated and proliferate, giving rise to a 
clone of cells with identical specificities. Interestingly, the lesions of apoE-deficient mice 
have shown oligoclonal expansion of T cells, indicating that the T cell population has 
expanded due to local antigenic stimulation (Paulsson et al. 2000). One of the clones 
expressed TCR-Vβ6, a receptor type that is also expressed by T cells recognizing oxLDL. In 
contrast, such clonal expansion could not be detected in human advanced atherosclerotic 
lesions, a result that might be explained by the presence of a more chronic type of 
inflammation in older plaques (Stemme et al. 1991; Swanson et al. 1994; Oksenberg et al. 
1997). However, to support the role of intimal antigens in the local activation of adaptive 
immunity, T cells reactive with oxLDL (Stemme et al. 1995), HSPs (Benagiano et al. 2005), 
EBV (Boer de et al. 2005), and chlamydial antigens (Mosorin et al. 2000; Boer de et al. 2000) 
have been isolated from human atherosclerotic plaques. It is of special interest, that the 
percentage of recently activated T lymphocytes was found to be increased in the culprit 
lesions of patients with acute coronary syndromes (Hosono et al. 2003), and that the T cells of 
unstable plaques showed signs of specific, antigen-driven activation (De Palma et al. 2006). 
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In addition, in acute coronary syndromes, the peripheral blood lymphocyte response is 
directed against plaque antigens (Caligiuri et al. 2000). These results suggest that activation of 
T lymphocytes may play a role in the destabilization of plaques. Accordingly, most studies on 
experimental animals suggest that, as a group, T cells are proatherogenic. Thus, the absence 
of CD4+ T cells has been shown to reduce lesion formation in apoE-/- mice (Zhou et al. 2005), 
while transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apoE-/- mice 
(Zhou et al. 2000).  
 
CD4+ T lymphocytes have been divided into subgroups based on the cytokines they secrete, 
and these subgroups have been suggested to play somewhat opposing roles in the 
pathogenesis of atherosclerosis. Thus, Th1 cells, which produce cytokines that promote cell-
mediated immunity (IFN-γ, IL-1, TNF-α, and IL-2), have been regarded to promote 
atherogenesis. In contrast, Th2 cells, which secrete cytokines involved in antibody production 
(IL-4, IL-5, IL-10, and IL-13), have been suggested also to mediate anti-atherogenic effects. 
Recently, a third subgroup of regulatory T cells has gained much attention in atherogenesis. 
These cells are further divided into IL-10-producing Tr1 cells and TGF-β-producing Th3 
cells, and they exert many immunoregulatory functions, play a critical role in the maintenance 




The Th1 type of response, favoring a proinflammatory cell-mediated immune reaction, is 
suggested to prevail in atherosclerotic lesions. Thus, lesional T cells, especially in early 
lesions, have largely the properties of the Th1 subtype, and a large proportion of human 
atherosclerotic lesions contain IL-2 and IFN-γ, two important Th1-derived cytokines 
(Frostegård et al. 1999). Accordingly, various factors that promote the Th1 type immune 
response, e.g. IL-12 (Uyemura et al. 1996), IL-18 (Mallat et al. 2001a), and osteopontin 
(O'Brien et al. 1994) have been demonstrated in lesions. The Th1 type immune response has 
been suggested to promote atherogenesis. Thus, Th1 cytokines have been shown to activate 
macrophages, induce endothelial dysfunction, and promote plaque destabilization by 
inhibiting SMC proliferation and collagen synthesis, by inducing SMC apoptosis, and by 
increasing the secretion of matrix-degrading enzymes (Raines & Ferri 2005; Daugherty et al. 
2005; Østerud & Bjørklid 2003; Geng et al. 1996). Accordingly, animal studies have 
supported this pro-atherogenic role of the Th1 type response. Administration of exogenous 
IL-12 (Lee et al. 1999), IL-18 (Whitman et al. 2002b), or IFN-γ (Whitman et al. 2000) has 
been shown to lead to increased atherosclerosis in apoE-/- mice. In this mouse model, IL-18 
has also been shown to induce structural changes, such as decreased collagen content of 
plaques, which increases plaque instability (Mallat et al. 2001b; Nooijer de et al. 2004). In 
accordance with these results, apoE-/- mice with genetic deficiency of IL-18 (Elhage et al. 
2003), IFN-γ (Whitman et al. 2002a) or TNF-α (Brånen et al. 2004) showed decreased 
atherosclerosis. Futhermore, treatment of apoE-/- mice with pentoxifyllin, which inhibits Th1 
differentiation, decreased lesion formation (Laurat et al. 2001), and promotion of the Th1 type 




In contrast to Th1 cytokines, Th2 cytokines are scarce in human atherosclerotic plaques 
(Frostegård et al. 1999; Uyemura et al. 1996; Mallat et al. 1999b). However, based on the 
results of animal studies, it has been suggested that a shift toward the Th2 type response may 
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occur during the progression of atherosclerosis. Thus, severe hypercholesterolemia has been 
shown to shift the initial Th1 type autoimmune response toward the Th2 response in apoE-/- 
mice, as reflected by the increased levels of Th2-dependent anti-oxLDL IgG1 antibodies, the 
increased number of IL-4 and IL-10-producing T cells in the spleen, and the infiltration of IL-
4-producing T cells into atherosclerotic lesions (Zhou et al. 1998). Many studies have 
suggested an atheroprotective role for the Th2 response, an effect mediated at least partly by 
suppression of the Th1 type pro-inflammatory response (Uyemura et al. 1996). Indeed, in 
atherosclerotic lesions, areas containing the Th2 cytokine IL-10 show reduced apoptosis and 
expression of inflammatory genes, reflecting weakening of the Th1 response (Mallat et al. 
1999b). Furthermore, experiments with mice models have shown that overexpression of IL-10 
by T lymphocytes leads to decreased atherosclerosis, and accordingly, IL-10 deficiency leads 
to increased atherosclerosis (Pinderski Oslund et al. 1999; Pinderski et al. 2002; Mallat et al. 
1999a; Caligiuri et al. 2003). In addition, induction of the Th2 type of immune response has 
also been suggested to play a role in the atheroprotection observed in apoE-/- in response to 
immunization with MDA-LDL (Binder et al. 2004; Fredrikson et al. 2005). However, some 
data indicates that the Th2 type response could also mediate proatherogenic effects. Indeed, 
IL-4 has been shown to regulate various processes that can be regarded as potentially 
proatherogenic, such as monocyte recruitment and lipoprotein modification, and genetic 
deficiency of IL-4 is associated with decreased atherosclerosis in LDLR-/- mice (King et al. 
2002).  
 
Regulatory T lymphocytes 
Regulatory T cells (Tregs) play an important role in the induction and maintenance of 
immunological tolerance. The Th3 and Tr1 types of Tregs have been suggested to be of 
special importance in acquired tolerance to oral antigens as well as altered self-peptides. 
These cells have been shown to suppress both the Th1 and Th2 of types of response 
predominantly via the production of two anti-inflammatory cytokines IL-10 and TGF-β 
(reviewed by Cottrez & Groux 2004). Both cytokines are present in atherosclerotic lesions 
(Mallat et al. 1999b; Frostegård et al. 1999) and have been shown to mediate antiatherogenic 
effects. Thus, TGF-β deactivates macrophages, inhibits the maturation of dendritic cells, 
inhibits T cell proliferation and differentiation, reduces the expression of adhesion molecules, 
and promotes matrix deposition (reviewed by Mallat & Tedgui 2002). Indeed, the inhibition 
of TGF-β signaling in mouse models of atherosclerosis either systemically or in T cells led to 
the generation of unstable plaques with large lipid cores, extensive inflammatory infiltrates, 
and a decreased collagen content (Mallat et al. 2001c; Lutgens et al. 2002; Gojova et al. 2003; 
Robertson et al. 2003). In addition, transfer of Tr1 cells with their cognate antigen reduced 
atherosclerosis in apoE-/- mice with a concomitant increase in the level of IL-10 but a decrease 
in the number of macrophages and T cells in the lesions (Mallat et al. 2003). Immunological 
tolerance mediated by Tregs may also explain the observed immune suppression and 
reduction in atherosclerosis in LDLR-/- mice after oral/nasal feeding of HSP-65 (Harats et al. 
2002; Maron et al. 2002). In addition to antigen-induced adaptive regulatory T cells, 
endogenous natural CD4+CD25+ regulatory T cells may play a role in the control of 
atherosclerosis. Accordingly, very recent paper showed that these natural regulatory T cells 
are efficient inhibitors of atherosclerosis in mice (Ait-Oufella et al. 2006).  
  
CD8+, γδ and NKT lymphocytes 
In addition, atherosclerotic lesions have been shown to contain minor populations of other 
types of T lymphocytes. Some cytotoxic CD8+ cells are present in the intima throughout 
lesion development (Jonasson et al. 1986). However, since CD8+ deficiency did not affect 
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lesion size in apoE-/- mice, they have been suggested to play only a minor role in 
atherogenesis (Elhage et al. 2004). Similarly, γδ T lymphocytes, which express γδ TCR (in 
contrast to the more common αβ TCR), have also been detected in atherosclerotic lesions 
(Kleindienst et al. 1993), and their absence only marginally decreased atherosclerosis in apoE-
/- mice (Elhage et al. 2004). In contrast, NKT lymphocytes, which share characteristics of 
both NK cells of innate immunity and T cells of adaptive immunity, have been suggested to 
play a role in atherogenesis. These cells recognize lipid and glycolipid antigens presented on 
CD1 molecules on antigen-presenting cells (Beckman et al. 1994), and upon activation, they 
can produce large amounts of cytokines of both the Th1 and the Th2 type. CD1-positive cells 
have been detected in human atherosclerotic lesions (Melian et al. 1999), and NKT 
lymphocytes have been shown to accumulate in atherosclerosis-prone areas of the aortic arch 
in LDLR-/- mice (Aslanian et al. 2005). Of interest, animal studies have demonstrated that 
C1d-dependent activation of NKT cells aggravates atherosclerosis (Major et al. 2004; Tupin 
et al. 2004; Nakai et al. 2004; Aslanian et al. 2005). 
 
2.4.2 B lymphocytes 
 
B lymphocytes give rise to antibody-producing plasma cells. However, this process of 
antibody production typically requires assistance from helper T cells. Thus, upon recognition 
of the specific antigen by surface IgM, B cells internalize the antigen, process it, and re-
express it on their surface MHC class II molecules for recognition by Th cells with similar 
specificity. Upon this interaction, Th cells become activated and provide additional signals 
such as costimulatory molecules and cytokines to promote B cell differentiation, somatic 
hypermutation, and immunoglobulin class switching. In addition, a subpopulation of B cells 
express CD1d, which suggests that they might be involved in the presentation of lipid 
antigens to NKT cells (Mizoguchi et al. 2002). B cells have been detected in low numbers in 
both human and murine atherosclerotic lesions (Millonig et al. 2002; Zhou & Hansson 1999), 
but these cells are more numerous in the adventitia and periadventitial tissue (Aubry et al. 
2004). Furthermore, lesions of Watanabe hyperlipidemic rabbits were shown to contain clones 
of immunoglobulin-producing plasma cells (Sohma et al. 1995). Indeed, immunoglobulins 
have been identified in human atherosclerotic lesions throughout the process of lesion 
development (Vlaicu et al. 1985b; Ylä-Herttuala et al. 1994). Although it is likely that part of 
the antibodies have entered the intima from plasma, the presence of mRNAs for the κ light 
and γ heavy chain of IgG in rabbit lesions suggests that immunoglobulins are also synthesized 
locally in atherosclerotic plaques (Sohma et al. 1995). As a group, B cells have been 
suggested to play an atheroprotective role, possibly by affecting both the generation of 
protective antibodies and the immune network in a more general way. In support of this 
notion, removal of the spleen, which harbors a significant proportion of memory B cells and 
plays an important role in B cell maturation, significantly increased atherosclerosis in apoE-/- 
mice, and transfer of B cells from atherosclerotic apoE-/- mice reversed this effect and 
protected mice from advanced disease (Caligiuri et al. 2002). In addition, complete B cell 
deficiency increased both the early and late stages of atherosclerosis in LDLR-/- mice (Major 
et al. 2002). In this regard, of special interest and importance might be a subpopulation of B 
cells called B-1 cells, which belong to innate immunity, produce IgM-type natural antibodies, 
are abundant in spleen, and are reported to be the source of protective antibodies after 
immunization of mice with MDA-LDL (Binder et al. 2004). These antibodies are discussed in 
more detail in the section B1 cells and natural antibodies. 
 
 







































Number of subjects Measured parameter Main results 
Salonen et al. 1992 MDA, Cu2+ IgG, IgM, IgA 30 cases, 30 controls (all healthy) progression of carotid atherosclerosis 
(IMT) 
IgG  (MDA) ↑ in cases 
Virella et al. 1993 Cu2+ IgG 33 patients undergoing angiography, 64 healthy 
controls 
coronary atherosclerosis no difference between groups 
Puurunen et al. 1994 MDA IgG 135 cases, 135 controls (all dyslipidemic) AMI during 5-year follow-up IgG ↑ in cases  
Maggi et al. 1994 Cu2+, MDA IgG, IgM 94 cases, 42 healthy controls severe carotid atherosclerosis  IgG  and IgM (Cu2+, MDA) ↑ in cases 
Armstrong et al. 1994 MDA IgG 87 cases, 60 healthy controls angiographically verified CAD IgG ↑ in cases 
Bergmark et al. 1995 Cu2+ IgG, IgM, IgA 62 cases, 62 healthy controls peripheral vascular disease antibodies ↑ in cases 
Boullier et al. 1995 MDA IgG 70 cases, 70 healthy controls angiographically verified CAD no difference between groups 
Bui et al. 1996 Cu2+ IgG 25 cases, 38 healthy controls angiographically-verified CAD  IgG ↑ in cases 
Uusitupa et al. 1996 Cu2+ IgG 91 NIDDM patients, 82 healthy persons cardiovascular event and carotid IMT 
during 10-year follow up 
no correlation between IgG and carotid IMT or 
CV events 
van de Vijver et al. 
1996 
MDA IgG 47 cases, 96 controls severe CAD (>80%) no correlation between IgG and severity of 
atherosclerosis 
Wu et al. 1997 Cu2+ IgG, IgM, IgA 119 cases, 138 controls (all healthy) AMI during 10- to 20-year follow-up IgG and IgA ↑ in cases 
Lehtimäki et al. 1999 Cu2+ IgG 58 cases, 34 controls angiographically verified CAD IgG ↑ in cases 
Orchard et al. 1999 Cu2+ IgG patients with type I diabetes (49 cases, 49 
controls)  
AMI, angina, CAD death IgG ↓ in cases 
Fukumoto et al. 2000 Cu2+ IgG 446 healthy persons carotid atherosclerosis (IMT) IgG ↓ related to increased IMT 
Erkkilä et al. 2000 Cu2+ IgG 101 cases, 314 controls (all with CAD) AMI IgG ↑ in cases (AMI) than in controls  
Hulthe et al. 2001a Cu2+, MDA IgG, IgM 388 healthy 58-year old men carotid and femoral atherosclerosis 
(IMT) 
IgG (Cu2+) ↑ related to increased 
carotid IMT, IgG (Cu2+) ↓ related to 
increased femoral IMT  
Hulthe et al. 2001b Cu2+, MDA IgG, IgM 102 hypercholesterolemic patients and 102 
healthy controls 
carotid atherosclerosis (IMT) IgM (Cu2+, MDA) ↓ related to increased IMT 
in controls  
Dotevall et al. 2001 MDA IgG, IgM 46 cases, 70 healthy or diabetic controls AMI  IgG ↑ and  IgM↓ in cases 
Inoue et al. 2001 MDA IgG 108 cases, 31 controls without CAD angiographically verified CAD  IgG ↑ in cases  
Meraviglia et al. 2002 Cu2+, MDA IgG 52 patients undergoing carotid endarterectomy progression of carotid restenosis during 
6 months follow-up  
IgG and IgM (Cu2+) ↑ related to progression 
Inoue et al. 2002 MDA IgG 39 cases, 25 controls AMI IgG ↑ in cases 
McDowell et al. 2002 MDA IgG 40 cases, 40 controls without CAD angiographically verified CAD no difference between the groups  
Shoji et al. 2003 Cu2+ IgG 103 patients with end-stage renal disease carotid atherosclerosis (IMT) IgG ↓  related to increased IMT 
Fredrikson et al. 2003a MDA-modified 
apoB-peptides  
IgG, IgM  227 persons (78 cases, 149 controls) carotid atherosclerosis (IMT) (AMI 
during follow-up)  
IgM ↑ related to increased IMT,  
IgM ↑ in cases 
Karvonen et al. 2003 Cu2+, MDA IgM, IgG 1022 middle-aged persons  carotid atherosclerosis (IMT) IgM ↓  related to increased IMT 
Rossi et al. 2003 MDA IgG 529 patients undergoing coronary angiography severity of coronary atherosclerosis no correlation between IgG and severity of 
coronary atherosclerosis 
Tornvall et al. 2003 Cu2+, MDA, 
HOCl 
IgG 88 cases, 88 healthy controls AMI, prognosis of AMI patients during 
11-year follow up 
IgG (Cu2+, MDA) ↑ in cases, no association 
between IgG and prognosis of cases  
Fernandes et al. 2004 Cu2+ IgG 15 cases, 15 controls with stable angina unstable angina IgG ↓  related to unstable angina 
Su et al. 2005 Cu2+, MDA IgG, IgM 226 patients with hypertension carotid atherosclerosis (IMT) during 4-
year follow-up 
IgM (Cu2+,MDA and PC) ↓  related to 
increased IMT 
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OxLDL autoantibodies of adaptive immunity 
Antibodies against oxLDL have been shown to be present in the circulation of both patients 
with atherosclerosis and healthy individuals. However, it is not known whether these 
antibodies play an active role in the pathogenesis of atherosclerosis, or whether they are 
markers of the extent of the diasease. Studies on atherosclerotic mice have suggested that the 
levels of anti-oxLDL antibodies reflect the extent of atherosclerosis (Palinski et al. 1995b). 
However, induction of their production by active immunization with differently generated 
types of oxLDL or passive addition of antibodies recognizing epitopes of aldehyde-modified 
LDL have been shown to significantly reduce lesion size (George et al. 1998b; Fredrikson et 
al. 2003b; Schiopu et al. 2004). The situation is even more complex in humans. Numerous 
clinical and epidemiological studies have quantified the levels of anti-oxLDL antibodies in 
order to assess their correlation with the severity and progression of atherosclerosis, but the 
results have been controversial. Thus, both IgM and IgG antibodies can be detected in healthy 
individuals as well as in patients with cardiovascular disease. In support of a protective or 
irrelevant role of oxLDL antibodies in atherogenesis, these antibodies are already present in 
healthy children with no cardiovascular risk even at concentrations much higher than in adults 
(Iughetti et al. 1999). Furthermore, various studies have shown an inverse association or no 
association between oxLDL antibodies, especially the IgM subtype, and cardiovascular 
disease (see Table 3). In contrast, several other studies have shown a positive correlation 
between the levels of anti-oxLDL antibodies and the risk factors of CVD, the severity of 
carotid atherosclerosis, and angiographically verified coronary artery disease and also 
demonstrated the predictive value of these antibodies in the progression of carotid 
atherosclerosis, the occurrence of myocardial infarction and cardiovascular mortality (see 
Table 3). To explain the controversial results, various explanations have been proposed. First, 
the antibody populations are heterogeneous, since the antibodies are generated due to the 
activation of both innate and adaptive immune responses. Second, the oxidation-specific 
epitopes they react with can be diverse. Third, individual variations in immune response and 
differences between study populations may have contributed to the results. Also differences in 
the methodology of determining antibody levels may have caused some variation, for 
instance, differences in the used antigen (Cu2+ vs. MDA-modification, the extent of oxidation, 
presence of immune complexes etc.) (reviewed by Virella & Lopes-Virella 2003). It is also 
worth remembering that an immune response to oxLDL may play different roles during the 
different stages of atherosclerosis. 
 
 
2.5 Effects of immune response on atherogenesis 
 
According to the current concepts, both innate and adaptive immune responses are activated 
in atherosclerosis. It is therefore intriguing to hypothesize that this disease process could be 
prevented by modulation of the immune response. During the last decade, genetic and other 
manipulations of the mouse immune system have provided us with increasing knowledge 
about the role of the immune system and its specific components in atherogenesis. In addition, 
comparison of the extent of atherosclerosis between patients with genetic or acquired immune 
defects and healthy controls has provided some data about the role of specific parts of the 
immunity in atherogenesis. 
 
In humans, a study investigating the effects of congenital defects in humoral immunity on 
atherosclerosis failed to detect any association between IgA deficiency or common variable 
immunodeficiency (CVID) and acute myocardial infarction (Hammar et al. 1998). In contrast, 
HIV infection, which reduces the number of CD4+ helper T cells, has been associated with 
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cardiovascular diseases (Paton et al. 1993), and the extent of the disease has been suggested to 
correlate with the intensity of immunodeficiency (Constans et al. 1995). Moreover, current 
antiretroviral therapy used to treat HIV has been suggested to promote atherosclerosis largely 
by causing lipid alterations and insulin resistance (Barbaro 2003). Regarding the deficiencies 
of innate immunity, it has been shown that various deficiencies of the classical complement 
pathway proteins, i.e. C2 and C4, correlated with increased cardiovascular disease (Jönsson et 
al. 2005; Nityanand et al. 1999). This has been suggested to result at least partly from 
ineffective handling of apoptotic cells and immune complexes, thus also predisposing these 
patients to systemic lupus erythematosus (SLE). Of the other complement deficiencies, MBL 
deficiency has been associated with increased atherosclerosis and acute coronary events 
(Tsutsumi et al. 2005). Furthermore, TLR Asp299Gly polymorphism that attenuates TLR4 
signaling is associated with decreased atherosclerosis and a reduced risk of acute coronary 
events in humans (Kiechl et al. 2002; Ameziane et al. 2003). However, some studies have 
failed to find such an association (Yang et al. 2003), and a recent report even suggested an 
increased risk of myocardial infarction in patients with Asp299Gly polymorphism (Edfeldt et 
al. 2004). Further support for the role of immune activation in the pathogenesis of 
atherosclerosis, is provided by the finding that patients with rheumatic diseases, i.e. 
rheumatoid arthritis and SLE, have a significantly increased risk of atherosclerosis compared 
to healthy controls, and this seems to be explained not only by traditional risk factors but also 
by other disease-related factors such as chronic inflammation and increased autoantibody 
titres (reviewed by Shoenfeld et al. 2005).  
 
In mouse models of atherosclerosis, the use of various modern techniques, e.g. genetic 
manipulation and bone marrow transplantation, has allowed the researchers to investigate the 
role of specific parts of the immune system in atherosclerosis. In atherosclerosis research, two 
mouse models are widely used: apoE- and LDL-receptor-deficient mice. Targeted genetic 
deletion of apoE in mice leads to severe hypercholesterolemia and spontaneous 
atherosclerosis, whereas deletion of LDL receptor leads to atherosclerosis especially when the 
mice are fed a high-fat diet. In addition to mice, rabbits have been used in experimental 
research of atherosclerosis. Rabbits are very sensitive to high-cholesterol diets and develop 
rapidly severe dyslipidemia and atherosclerotic lesions. In addition, rabbits with a mutation in 
low density lipoprotein receptors, which develop spontaneous hypercholesterolemia 
(Watanabe Heritable Hyperlipidemic (WHHL) rabbits), have also been used in atherosclerosis 
research. The evidence from animal studies suggests that activation of the immune system 
may have both pro- and antiatherogenic effects, and these effects can be modulated by other 
factors such as gender and diet. Many of these studies have been discussed in relation to 
specific issues in separate chapters, and they are also summarized in Table 4. Therefore, they 
are only discussed here briefly.  
 
In general, disruption of initial leukocyte infiltration into intima by genetic deletion of 
endothelial adhesion molecules, leukocyte integrins, or chemotactic molecules and their 
receptors have been reported to lead to decreased atherosclerosis. In regard to innate 
immunity, deficiency of pattern recognition receptors has been shown to decrease 
atherosclerosis, suggesting that these receptors mediate pro-atherogenic effects. In contrast, 
the role of CRP is controversial, and current data suggest only a minor, if any, role for it in 
murine atherosclerosis. However, it has been shown that transgenically expressed CRP can 
not activate the mouse complement system, and the consequences in mice are likely to differ 
significantly from those in humans (Reifenberg et al. 2005). In regard to complement itself, 
animal studies suggest that activation of the classical pathway, which is involved in 
opsonization, might be atheroprotective, whereas activation of the terminal pathway with  
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Table 4. Experimental studies on the effects of immune response on atherogenesis 
Defect or treatment Immunological effect Animal /mouse 
strain 
Atherosclerosis Reference 
Leukocyte infiltration and differentiation    
E-selectin deficiency  LDLR-/- ↓ Dong et al. 1998 
P-selectin deficiency  LDLR-/-, apoE-/- ↓ Dong et al. 1998; Dong et al. 2000; 
Johnson et al. 1997 
VLA4 blocking  LDLR-/- ↓ Shih et al. 1999 




 apoE-/-, LDLR-/- ↓ Aiello et al. 2002 
MCP-1 deficiency  LDLR-/- ↓ Gu et al. 1998 
CCR2 deficiency  apoE-/- ↓ Boring et al. 1998 
CXCR3 deficiency  apoE-/- ↓ Veillard et al. 2005 
CX3CR1 deficiency  apoE-/- ↓ Lesnik et al. 2003; Combadiere et al. 
2003  
CCR5 deficiency  apoE-/- ↔ Kuziel et al. 2003 
Met-RANTES antagonism of CCR1, and -5  LDLR-/- ↓ Veillard et al. 2004 
Cells of the innate 
immunity 
    
M-CSF deficiency lack of tissue macrophages apoE-/- ↓ Smith et al. 1995; Rajavashisth et al. 
1998 
Bone marrow transplant 
from Ly49a transgenic 
mice 
lack of functional NK cells  LDLR-/- ↓ Whitman et al. 2004 
Pattern-recognition 
receptors 
    
SRA deficiency  apoE-/- ↓ Suzuki et al. 1997 
CD36 deficiency  apoE-/- ↓ Febbraio et al. 2000 
TLR4 deficiency  apoE-/- ↔↓ Wright et al. 2000; Michelsen et al. 
2004b 
Acute-phase proteins     
CRP transgene  apoE-/- ↑ Paul et al. 2004 
CRP transgene  apoE-/- ↔ Hirschfield et al. 2005 
CRP transgene  apoE*3 Leiden  ↔ Trion et al. 2005 
CRP transgene  apoE-/- ↔ Reifenberg et al. 2005 
Complement system     
C6 deficiency   rabbit ↓ Schmiedt et al. 1998 
C5 deficiency  apoE-/- ↔ Patel et al. 2001 
C3 deficiency  apoE-/-/LDLR-/- ↑ Persson et al. 2004 
C3 deficiency  LDLR-/- ↑ lipids, ↓ 
maturation 




40-50% decrease in serum 
hemolytic activity (inhibition 
of complement activation) 
C57Bl/6 ↓ Thorbjornsdottir  et al. 2005 
T and B cells     
RAG1/RAG2 deficiency T and B cell defect apoE-/- ↔ Dansky et al. 1997; Daugherty et al. 
1997 
RAG2 deficiency T and B cell defect apoE-/- ↓ Reardon et al. 2001 
RAG1 deficiency T and B cell defect LDLR-/- ↓ (early) Song et al. 2001 
SCID/SCID T and B cell defect apoE-/- ↓ Zhou et al. 2000 
+ transfer of CD4+   apoE-/- ↑ Zhou et al. 2000 
CD4 deficiency  apoE-/- ↓ Zhou et al. 2005 
T-bet deficiency ↓ Th1 response LDLR-/- ↓ Buono et al. 2005 
Pentoxifylline treatment ↓ Th1 response apoE-/- ↓ Laurat et al. 2001 
IFNγR deficiency ↓ Th1 response, ↓ IFNγ effects apoE-/- ↓ Gupta et al. 1997 
IFNγ deficiency ↓ Th1 response apoE-/- ↓ Whitman et al. 2002a 
IL-18 deficiency ↓ Th1 response apoE-/- ↓ Elhage et al. 2003 
TNF-α deficiency ↓ Th1 response apoE-/- ↓ Brånen et al. 2004 
IFNγ treatment ↑ Th1 response apoE-/- ↑ Whitman et al. 2000 
IL-12 treatment ↑ Th1 response apoE-/- ↑ Lee et al. 1999 
IL-18 treatment ↑ Th1 response LDLR-/- ↑ Whitman et al. 2002b 
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Defect or treatment Immunological effect Animal /mouse strain Atherosclerosis Reference 
IL-10 transgenic ↑ Th2 response  LDLR-/- ↓ Pinderski et al. 2002 
IL-4 deficiency in bone 
marrow-derived cells 
↑ Th2 response LDLR-/- ↓ King et al. 2002 
IL-5 deficiency in bone-
marrow-derived cells 
↓ T15/E06 antibodies LDLR-/- ↑ Binder et al. 2004 
Inhibition of TGFβ 
signaling 
↓ regulatory T cell response apoE-/- ↑ more unstable 
plaque phenotype 
Mallat et al. 2001c; Lutgens et al. 
2002 
Injection of Treg cells ↑ regulatory T cell response apoE-/- ↓ Mallat et al. 2003 
B cell deficiency  LDLR-/- ↑ Major et al. 2002 
Splenectomy ↓ B cell response apoE-/- ↑ Caligiuri et al. 2002 
+ transfer of B cells  apoE-/- ↓ Caligiuri et al. 2002 
Others     
IgG injections immunosuppression apoE-/- ↓ Nicoletti et al. 1998 
IgG inj. (C3+/+ / -/- mice)  LDLR-/- ↓ (C3+/+) 
↔ (C3-/-) 
Persson et al. 2005 
Disruption of CD40-
CD40L interaction 
 apoE-/-, LDLR-/- ↓↔↔ more stable 
plaque phenotype 
Mach et al. 1998; Schönbeck et al. 
2000; Lutgens et al. 2000 
B7-1/B7-2 deficiency defects in T cell responses LDLR-/- ↓ Buono et al. 2004 
Sirolimus injections ↓ Th1 and Th2 cytokines, 
except ↑ TGF-β 
apoE-/- ↓ Elloso et al. 2003 
Immunization     
MDA-LDL s.c./i.m. α-MDA-LDL IgG ↑ WHHL rabbits ↓ Palinski et al. 1995a 
OxLDL/nLDL s.c. α-oxLDL IgG ↑ NZ rabbits ↓ Ameli et al. 1996 
Cholesterol-rich 
liposomes i.m. 
α-cholesterol IgG, IgM↑ NZ rabbits ↓ Alving et al. 1996 
MDA-LDL s.c. α-MDA-LDL IgG ↑ apoE-/- ↓ George et al. 1998b 
MDA-LDL/nLDL i.p. α-MDA-LDL IgG ↑/ ↔ LDLR-/- ↓ Freigang et al. 1998 
MDA-LDL s.c. α-MDA-LDL IgG ↑ apoE-/- ↓ Zhou et al. 2001 
ApoB-100 peptides 
sequences 
α-native and MDA-modified 
apoB-100 sequence IgG ↑ 
C57Bl/6 ↓ Fredrikson et al. 2003b; Fredrikson 




sequences IgG ↑ 
apoE-/- ↓ Fredrikson et al. 2005 
ApoB-100 peptide 
sequence s.c./i.p. 
α-apoB-100 sequence (peptide 
2) IgM ↑ 
apoE-/- ↓ (with peptide 2) Chyu et al. 2005 
Heat-killed R36a  
Str. pneumoniae s.c./i.p. 
α-oxLDL IgM (T15) ↑, 
expansion of oxLDL-spesific B 
cells  
LDLR-/- ↓ Binder et al. 2003 
Passive immunization 
with anti-MDA-modified 
apoB-100 IgG1 i.p. 
 C57Bl/6 ↓ Schiopu et al. 2004 
Passive immunization 
with anti-MDA-modified 
apoB-100 IgG1 i.p. 




 apoE-/- ↓ Faria-Neto et al. 2005 




↑ Xu et al. 1992 
Mycobacterium 
tuberculosis/ HSP65 s.c. 
cellular immune response to 
HSP65 ↑ 
C57Bl/6 ↑ George et al. 1999b 
Mycobacterium 
tuberculosis/ HSP65 s.c. 
cellular immune response to 
HSP65 ↑, α-HSP65 IgG ↑  
LDLR-/- ↑ Afek et al. 2000 
HSP65 p.o. cellular immune response to 
HSP65 ↓, Th2 type response ↑ 
LDLR-/- ↓ Harats et al. 2002 
HSP65 p.o./intranasally cellular immune response to 
HSP65 ↓, Th2 type response ↑ 
LDLR-/- ↓ Maron et al. 2002 
β2GPI s.c. both cellular and humoral 
immune response to β2GPI ↑ 
LDLR-/- ↑ George et al. 1998a 
β2GPI s.c. humoral immune response to 
β2GPI ↑ 
apoE-/- ↑ Afek et al. 1999 
β2GPI p.o. cellular immune response to 
β2GPI ↓ 
LDLR-/- ↓ George et al. 2004 
IL-12-PADRE 
vaccination i.m. 
generation of antibodies that 
blocked IL-12 function 
LDLR-/- ↓ Hauer et al. 2005 
     
s.c., subcutaneously; i.c., intracutaneously; i.p., intraperitoneally; p.o., perorally; i.m., intramuscularly 
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many pro-inflammatory effects would rather promote atherogenesis. Adaptive immunity as a 
whole has been suggested to mediate proatherogenic effects. Thus, mice that are deficient in 
Rag-1 or Rag-2, which leads to a lack of functional T and B lymphocytes, develop less 
atherosclerosis than control mice. However, this effect was observed only at lower serum 
cholesterol levels, and the effect disappeared when the mice were fed a high-fat diet and 
developed higher serum cholesterol levels (Dansky et al. 1997; Daugherty et al. 1997; 
Reardon et al. 2001; Song et al. 2001). At high cholesterol levels, the protective effect of 
immune deficiency may be overruled by excessive hypercholesterolemia or, alternatively, 
qualitative differences of immune activity, such as a shift from the Th1 to the Th2 type of 
response, may occur under severe hypercholesterolemia and hence explain the results. 
Consistently, disruption of costimulatory signaling (such as CD40-CD40L and B7-1/2-
CD28), which is essential for the efficient activation of adaptive immunity, decreases 
atherosclerosis (Mach et al. 1998; Buono et al. 2004). Furthermore, intravenous injection of 
immunoglobulin G, which is known to modulate and suppress the immune response by 
various mechanisms, decreases atherosclerosis (Nicoletti et al. 1998). Interestingly, a recent 
study showed that this effect actually depended on the intactness of the complement system 
(Persson et al. 2005). Furthermore, it has been shown that pro-atherogenic effects of adaptive 
immunity are mediated mainly via CD4+ cells, since transfer of CD4+ cells from 
atherosclerotic mice to immunodeficient recipients aggravated atherosclerosis (Zhou et al. 
2000), especially when the T cell population was derived from oxLDL-immunized mice 
(Zhou et al. 2006). However, the current concepts suggest that different subgroups of CD4+ 
cells may have opposite effects on atherosclerosis. Thus, while evidence indicates that the 
Th1 type of immune response is pro-atherogenic, the Th2 type of response may confer some 
atheroprotective effects. Furthermore, both types of responses are under control of regulatory 
T cells, which, by suppressing and controlling immune activation, mediate anti-atherogenic 
effects. In addition, B cells have been suggested to perform mainly atheroprotective functions. 
In support of this notion, complete B cell deficiency increased both the early and late stages of 
atherosclerosis in LDLR-/- mice (Major et al. 2002). In addition, removal of the spleen, which 
harbors a significant proportion of memory B cells and plays an important role in B cell 
maturation, significantly increased atherosclerosis in apoE-/- mice, which effect was reversed 
by the transfer of B cells from atherosclerotic apoE-/- mice (Caligiuri et al. 2002).  
 
In addition to genetic modifications, various immunization studies have given insights into 
the role of immune response in atherogenesis (Tables 4 and 5). Since various studies have 
suggested that activation of the immune response might have harmful effects in atherogenesis, 
and elevated antibody levels against oxLDL correlated with the extent of atherosclerosis, it 
was somewhat surprising that parenteral immunization of animals with MDA-modified or 
Cu2+-oxidized LDL or with peptide fragments of MDA-modified apoB-100 suppressed 
atherogenesis. In these studies, a decrease in the extent of atherosclerosis correlated with an 
increase in T cell-dependent IgG antibodies against immunogen, suggesting that antibodies 
might be involved in mediating this protective effect. In addition, immunization seemed to 
promote the Th2 type of response, which was also involved in the induction of natural IgM 
antibodies that have been suggested to exert atheroprotective effects (Fredrikson et al. 2005; 
Binder et al. 2004; Binder et al. 2003). Similarly, passive immunization of apoE-/- mice with 
IgG1 antibodies against MDA-modified apoB-100 sequences inhibited atherosclerosis 
(Schiopu et al. 2004). In contrast to oxLDL, parenteral immunization with HSP65 has been 
shown to aggravate atherosclerosis in animal models. In immunized animals, the T cell 
proliferative response to HSP65 was increased, whereas the production of anti-HSP 
antibodies did not correlate with the extent of lesions, suggesting that activation of cell-
mediated immunity might be responsible for the proatherogenic effects of HSP immunization, 
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possibly via an autoimmune attack against stressed vascular cells. Since mucosal 
administration of antigens has been shown to induce tolerance by a mechanism probably 
involving regulatory T cells (Cottrez & Groux 2004), Maron et al. tested whether mucosal 
administration of HSP65 would affect the extent of atherosclerosis. Indeed, in response to 
oral/nasal administration of HSP65, atherosclerosis-prone mice developed less 
atherosclerosis, and the effect was associated with suppressed T cell reactivity against HSPs, 
decreased IFNγ-production, and increased expression of Th2-dependent antibodies and 
cytokines (Maron et al. 2002; Harats et al. 2002). Similarly, although parenteral 
immunization with β2GPI aggravated atherosclerosis in both LDLR-/- and apoE-/- mice 
(George et al. 1998a; Afek et al. 1999), induction of oral tolerance significantly decreased 
atherosclerosis (George et al. 2004). Thus, it appears that regulatory T cells play an important 
role in mediating atheroprotective effects and might hence present a possible target for 
therapeutic developments. The type of immune responses evoked by different immunization 
routes and their effects on atherogenesis are further summarized in Table 5. 
 
Table 5. Summary of the effects of immunization or induction of tolerance on 
atherosclerosis in mouse models  
   
 Immunological response Atherosclerosis 
   
Parenteral immunization   
oxLDL/MDA-LDL/apoB peptides IgG and IgM titers against antigen ↑  
Th2 type of immune response ↑ 
↓ 
HSP65 Proliferative response of T cells to HSP ↑ ↑ 
β2GBI Ig titers against  β2GBI ↑  
Proliferative response of T cells to β2GBI ↑ 
↑ 
Heat-killed R36a  
Str. pneumoniae 
IgM titers against oxLDL phosphocholine ↑ 
Expansion of oxLDL-spesific T15-IgM-
secreting B cells 
↓ 
   
Mucosal immunization - tolerance   
HSP65 Proliferative response of T cells to HSP ↓  
IgG titers against HSP ↓  
Expression of Th1 cytokines ↓  
Expression of Th2 cytokines ↑ 
↓ 
β2GBI Proliferative response of T cells to β2GBI ↓ 
Th2 cytokines ↑  
Th1 cytokines ↔ 
↓ 
   
Neonatal immunization - tolerance   
oxLDL IgG and IgM titers ↓  
proliferative response of T cells to oxLDL ↓ 
↓ 
   
Passive immunization with antigen-
specific antibodies 
  
Anti-MDA-apoB peptides (IgG1)  ↓ 
Anti-phosphocoline (IgM)   ↓ 
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III AIMS OF THE STUDY 
 
 
Complement system is part of the innate immune system. Studies on experimental animals 
suggest that complement system also plays a role in atherogenesis. Complement is activated 
in atherosclerotic lesions, and lesions have been shown to contain various activators of the 
complement system, e.g. modified lipoproteins and oxLDL-IgG immune complexes. When 
activated, the cascade-like activity of the complement generates various effector molecules 
(opsonins, anaphylatoxins, C5b-9), which can regulate the inflammatory response and act 
together to destroy their target structures. To prevent uncontrolled complement activation or 
its attack against normal host cells, complement needs to be under strict control by regulatory 
proteins.  
 
The present thesis concentrates on elucidating the role of the complement regulators, effectors 
and activators in atherosclerotic lesions. The specific aims of the study were: 
 
1. To analyze the presence and localization of two complement regulators, factor H and C4bp, 
in human atherosclerotic lesions, and to elucidate their functional role in atherosclerotic 
lesions (Studies I and II). 
 
2. To analyze whether receptors of the two complement-derived anaphylatoxins, C3a and 
C5a, are present in atherosclerotic lesions, and to characterize the cell types expressing them 
(Study III). 
 
3. To investigate, whether oxLDL-IgG immune complexes, in addition to activating the 
classical complement pathway, could have direct effects on the intimal cells. Spesifically, we 
wanted to study, whether oxLDL-IgG immune complexes affect the survival of cultured 
human monocytes and what are the receptors and downstream signaling events involved in 
this process (Study IV). 
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IV MATERIALS AND METHODS 
 
 
The methods used in this study are summarized in Table 6, and the techniques have been 
described in greater detail in the original publications listed in the Table. Thus, only a short 
overview of the materials and methods used is provided here. The antibodies used in the 
immunohistochemistry, Western blotting, and blocking experiments are listed in Table 7. In 
the body of the text, no references are given, and they can be found in the respective 
publications. 
 
Table 6. Methods 
    
Method   Used in publications Reference 
Immunohistochemistry I, II, III  
Extraction and purification of proteoglycans I, II  Öörni et al. 1997 
Affinity chromatography I, II  
Surface-plasmon resonance analysis I Jokiranta et al. 2001 
Complement activation assays I  
Western blotting I, IV  
RNA isolation III  
RT-PCR  III  
Isolation of LDL I, IV Havel et al. 1955 
Modifications of LDL    
                   oxidation IV  
                   enzymatic modification I Chao et al. 1992 
Determination of TBARS IV Hessler et al. 1983 
High-performance thin-layer chromatography IV  
Isolation and culture of of human monocytes III, IV Saren et al. 1996 
Determination of endotoxins IV  
Protein quantitation with Lowry IV  Lowry et al. 1951 
Preparation of immune complexes  IV  
Isolation of human anti-oxLDL antibodies IV Koskinen et al. 1998 
Determination of M-CSF with ELISA kit IV  
Cell viability assay (WST) IV  
Thymidine incorporation assay  IV  
Determination of apoptosis:    
 TUNEL IV  
 DNA fragmentation (ELISA) IV  
 active caspase-3 (ELISA) IV  
Blocking studies:   
 blocking the effect of M-CSF IV  
 blocking the activation of the Akt pathway IV  
  blocking Fcγ receptors IV   
    
 
 
Human coronary artery and aortic samples 
Coronary artery specimens and aortas were obtained at autopsy at the Department of Forensic 
Medicine, University of Helsinki, 27 to 216 hours after the death of patients who died of non-
cardiac causes. Segments with and without evident atherosclerotic plaques were taken from 
the left anterior descending arteries. In addition, segments of the left and right human 
coronary arteries were obtained freshly from recipient hearts at the time of cardiac 
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transplantation or from hearts of organ donors who had been excluded from transplantation 
due to size, tissue type mismatch, or coronary atherosclerosis in Helsinki University Central 
Hospital. Informed consent was obtained from each patient. Patients with malignancies or 
chronic inflammatory diseases were excluded from the study. Institutional Ethics Committees 
had approved the study protocol, and the study was conducted in accordance with the Helsinki 
Declaration.  
 
The samples were either embedded in OCT and snap-frozen in liquid nitrogen, or fixed in 
10% neutral-buffered formalin and embedded in paraffin according to standard procedures. 
Frozen (8 µm) or paraffin (4 µm) sections were cut, stained with hematoxylin-eosin, and 
evaluated microscopically to classify the atherosclerotic lesions according to the guidelines of 
the American Heart Association. For PCR analysis, only freshly obtained coronary samples 
were used to avoid any bias caused by the postmortem changes in RNA. These segments were 
snap-frozen in liquid nitrogen, after which the adventitia of the coronary arteries was carefully 
removed and the absence of the adventitial layer was verified by Masson Trichrome staining. 
The division of samples into normal and atherosclerotic ones was done based on macroscopic 
analysis. 
 
Extraction and purification of aortic proteoglycans 
Proteoglycans were isolated from the intima-media of human aortas obtained at autopsy 
within 24 h of accidental death. Briefly, proteoglycans were extracted from intima-media at 
4°C for 24 h with 15 volumes of buffer containing 6 M urea and protease inhibitors. After 
extraction, the mixture was centrifuged at 100 000 g for 60 minutes. The supernatant was 
diluted with 6 M urea to give a final concentration of 0.25 M NaCl and loaded on a HiTrap Q 
column. The proteoglycans were eluted with a linear gradient of 0.25 to 1.0 M NaCl, and the 
peaks at 280 nm were collected, dialyzed against water and lyophilized. The quantities of 
proteoglycans were expressed in terms of their glycosaminoglycan contents.  
 
Isolation and modifications of low-density lipoprotein 
Human LDL (d = 1.019-1.050 g/ml) was isolated from plasma of healthy volunteers by 
sequential ultracentrifugation under aseptic conditions in the presence of 3 mM EDTA. LDL 
was dialyzed to a buffer containing 1 mM EDTA and 150 mM NaCl (pH 7.4).  
 
E-LDL was prepared by modification of LDL by trypsin and cholesterol esterase. Briefly, 
LDL (2 mg/ml protein) was first treated with trypsin from bovine pancreas in PBS at +37°C 
for 2 h after which trypsin was inhibited with 64 µg/ml Soybean trypsin inhibitor in PBS. 
Finally the mixture was incubated with 80 µg/ml cholesterol esterase from Candida 
cylindracea in PBS at +37°C for 2 h. E-LDL was purified by gel filtration on a Bio-Gel A-
0.5m column, and its concentration was determined from its cholesterol content. 
 
Oxidized LDL was prepared by first removing EDTA from LDL by PD-10 column, and then 
incubating LDL (1 mg/ml) with 10 µM CuSO4 at 37°C for 18 h. Oxidation was terminated by 
the addition of EDTA (100 µM) and by cooling the sample on ice. The extent of oxidation 
was determined by measuring thiobarbituric acid-reactive substances (TBARS).   
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Isolation and culture of human monocytes 
Human mononuclear leukocytes from healthy subjects were isolated from buffy by Ficoll-
Paque gradient centrifugation. Mononuclear cells were resuspended in DMEM supplemented 
with penicillin and streptomycin, and plated on cell culture wells. After 30 min at 37°C in 5% 
CO2, the cells were washed with PBS to remove non-adherent cells, and SFM medium 
supplemented with antibiotics was added. After 18 h, the cells were washed three times with 
PBS, and experiments with monocytes were started with fresh SFM medium supplemented 
with antibiotics. For some experiments, monocytes were cultured in the presence of GM-CSF 
(10 ng/ml) for 7 days to allow their differentiation into macrophages. 
  
Cells of the human monocytic cell-line THP-1 were grown in RPMI 1640 medium 
supplemented with 10% fetal calf serum and antibiotics. To induce their maturation, the cells 
were grown in the presence of 200 nM phorbol 12-myristate 13-acetate (PMA) for 3 days.  
 
Isolation of anti-oxLDL antibodies 
Anti-human oxLDL antibodies were isolated from freshly obtained human serum. Briefly, 
LDL was coupled to a NHS-HiTrap column and oxidized by 10 µM CuCl2 for 18 h at +37°C. 
Oxidation was finished by extensive washing with buffer containing 200 µM butylated 
hydroxytoluene and 300 µM EDTA. To isolate anti-oxLDL antibodies, 10 ml of serum, 
obtained from healthy volunteers, was diluted 1:4 in 0.01 M NaHCO3, pH 8.3 and applied 
into the oxLDL column. After 18 hours’ incubation at +4°C, the column was extensively 
washed with the buffer, after which anti-oxLDL antibodies were eluted from the column with 
0.1 M NaHCO3, 0.5 M NaCl, pH 8.3. The protein concentrations of eluate fractions were 
determined by the method of Lowry. The purity of eluted antibodies was verified with SDS-
PAGE, and ELISA assay was done to confirm that the isolated antibodies specifically bound 
to oxLDL.  
 
Human recombinant antibodies (clones LDO 107 Z3 IEI-E3 and CT-17, both IgG1) against 
MDA-modified apoB-100-derived peptides were a kind kift from Dr. B. Jansson (BioInvent 
International AB, Lund, Sweden).  
 
Immunohistochemistry 
Frozen and paraffin sections were stained by using an indirect immunoperoxidase or 
immunofluoresence method. Briefly, the paraffin sections were deparaffinized in xylene and 
rehydrated through a series of graded alcohols. The frozen sections were fixed either in 
methanol for 10 minutes or in ice-cold acetone for 2 minutes. The slides were incubated with 
2% H2O2 to block endogenous peroxidase activity and then with 3% normal serum (rabbit, 
horse, or goat) to reduce non-specific binding of antibodies, each for 30 minutes at room 
temperature. Primary antibodies were incubated overnight at +4°C. To obtain a color signal, 
the primary antibodies were detected using the commercial avidin-biotin complex system with 
3-amino-9-ethylcarbazole as a chromogen. Thereafter, the sections were counterstained with 
hematoxylin and mounted using Aquamount or Permount. To obtain a fluorescent signal, the 
primary antibodies were detected using various isotype-specific Alexa-conjugated secondary 
antibodies, or alternatively, the biotinylated secondary antibodies were detected by incubating 
the slides with streptavidin-FITC. The nuclei were stained with 4’,6-diamino-2-phenylindole 
(DAPI), and the sections were mounted using fluorescent mounting media. As negative 
controls, the primary antibodies were replaced with non-specific rabbit IgG or isotype-
matched mouse IgGs. 
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Western blotting 
Immunoblotting was used to analyze the proteins of homogenates of human arteries and 
lysates of human monocytes. In brief, samples were run into a 10% SDS-page gel under 
nonreducing conditions and electrotransferred onto a nitrocellulose membrane. Nonspecific 
binding sites were blocked by incubating the membrane for 1 hour in 5% fat-free milk. The 
membranes were then probed overnight at +4°C with primary antibodies (see table 7). After 
washing, the membranes were incubated for 1 h at room temperature with HRP-conjugated 
secondary antibodies and washed, and the immunoreactive bands were visualized on an x-ray 
film by enhanced chemiluminescence. In some experiments, the membranes were then 
stripped and probed again overnight at +4°C with other primary antibodies. The immunoblots 
were quantitated by densitometric scanning with a Gel Doc 2000 gel documentation system. 
 
Affinity chromatography and surface-plasmon resonance analysis 
Human aortic proteoglycans were coupled to a NHS-activated HiTrap column, and human 
factor H, C4bp, or CRP was injected into the column that had been equilibrated with buffer 
containing 10 mM HEPES, pH 7.4, and either 2 mM CaCl2 or 100 µM EDTA. The material 
bound to the column was then eluted with a gradient of NaCl (0  250 mM) in a high-
performance FPLC system. The elution was monitored by UV absorbance at 280 nm and the 
NaCl gradient by conductometry. 
 
Surface plasmon resonance measurements were performed using the BIACORE 2000® 
instrument and the BIAevaluation software V 3.0 as described previously (Jokiranta et al. 
2001). Human factor H and human CRP were immobilized on carboxylated dextran CM5 
sensor chips, and analyses of binding with human aortic proteoglycans were performed using 
1/3 veronal-buffered saline. In control experiments, the sensor chips were treated identically, 
except that no protein was coupled to the chip. 
 
RNA isolation and RT-PCR 
For PCR analysis, only freshly obtained coronary samples were used in order to avoid any 
bias caused by postmortem changes in RNA. Total RNA was isolated from the intima-medias 
of coronary arteries using ultra-pure TRIzol reagent and a commercial RNA isolation kit, 
including deoxyribonuclease digestion. After that, 0.25 µg of purified total RNA was 
transcribed into cDNA with a Superscript TM pre-amplification system. The PCR product 
was verified by DNA sequencing to represent the corresponding target. The RT-PCR assay 
was standardized to the expression level of the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).  
 
Preparation of insoluble oxLDL-IgG immune complexes 
Before preparing oxLDL-IgG immune complexes, rabbit anti-LDL antibody was dialyzed 
against sterile PBS to remove NaN3. Insoluble ICs were prepared by incubating rabbit anti-
LDL antibody (200 µg/ml) with oxLDL (125 µg/ml) or in sterile PBS overnight at +4°C. The 
concentrations of oxLDL and anti-LDL antibodies used to prepare ICs were determined by a 
precipitin curve. After incubation, the precipitate was centrifuged at 10 000 rpm and 
resuspended in sterile PBS. The protein content of oxLDL-IgG ICs was determined by the 
Lowry assay and the cholesterol content with a commercially available kit. In some  
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Table 7. List of primary antibodies 
Antigen Clone/cat.no. Host Isotype 
Working 
dilution Source/ref. Study 
Immunohistochemistry       
C3d A0063 rabbit  1:500 DAKO I, III 
sC5b-9 neoantigen A239 mouse IgG2bk 3.3 µg/ml Quidel I, II, III 
ApoB-100 2-B4 mouse IgG2b 10 µg/ml ICN Pharm I 
CRP CRP-8 mouse IgG1 29 µg/ml Sigma I 
CRP A29 rabbit  1:500 Biomeda I 
Versican LF99  rabbit  1:100 Bernstein et al. 1995 I 
Factor H  goat  1:300 Incstar  I 
C3aR 8H1 mouse IgG1 10 µg/ml BD III 
C3aR BIIG1 mouse IgG2a 8 µg/ml  Monsinjon et al. 2001 III 
C3aR BIIG2 mouse IgG2a 8 µg/ml  Monsinjon et al. 2001 III 
C3aR  rabbit  4 µg/ml Gasque et al. 1998 III 
C3aR sc-14621 goat   1 µg/ml SCBT III 
C3aR ab7209 rabbit  10 µg/ml Abcam III 
CD88 S5/1 mouse IgG2a 10 µg/ml Serotec III 
CD88 W17/1 mouse IgG1 10 µg/ml Serotec III 
Macrophage  HAM56 mouse IgG1 0.7µg/ml DAKO I, III 
CD68 (macrophage) PG-M1 mouse IgG3 7.2 µg/ml DAKO I, III 
CD43 (T cell) DF-T1 mouse IgG1 2.65 µg/ml DAKO III 
CD45RO UCHL-1 mouse IgG2a 7.5 µg/ml DAKO III 
CD3 (T cell) A0452 rabbit  10 µg/ml DAKO III 
Tryptase (mast cell) G3 mouse IgG1 1.5 µg/ml DAKO III 
Tryptase (mast cell)  rabbit  0.6 µg/ml Harvima et al. 1988 III 
Actin (muscle) HHF35 mouse IgG1 1 µg/ml DAKO III 
α-actin (SMC) 1A4 mouse IgG2a 0.5 µg/ml DAKO III 
CD31 (endothelial cell) JC/70A mouse IgG1 10 µg/ml DAKO III 
VE-cadherin BV6 mouse IgG2a 10 µg/ml Chemicon III 
HLA-DP, DQ, DD antigen  CR3/43 mouse IgG1 2.3 µg/ml DAKO III 
C4bp  mouse IgG 5.5 µg/ml Hardig et al. 1997 II 
C4bp A215 mouse IgG2bk 20 µg/ml Quidel II 
Protein S HS3 mouse IgG1 20 µg/ml Sigma II 
Cleaved caspase-3 9661 rabbit  1:50 Cell Signaling II 
Properdin  goat  1.6 µg/ml Incstar II 
Western blotting       
Factor H   goat  1:5000 Calbiochem  I 
SCR19-20   rabbit  1:1000 A kind gift from Dr. Jens 
Hellwage 
I 
Factor H 196X8   mouse IgG 5 µg/ml Jokiranta et al. 1996 I 
Phospho-Akt 4058S rabbit (mAb)  1:1000 Cell signaling Tech. IV 
Akt c-20 goat  0.4 µg/ml Santa Cruz IV 
Blocking experiments       
M-CSF 26730 mouse IgG2a 10 µg/ml R&D Systems IV 
CD64 (FcγR I) 10.1 mouse  F(ab)2 20 µg/ml Ancell IV 
CD32 (FcγR II) 7.3 mouse  F(ab)2 20 µg/ml Ancell IV 
Preparation of ICs       
LDL BT-905 rabbit   Biomedical Technologies  IV 
KLH H0892 rabbit   Sigma IV 
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experiments, native LDL-IgG ICs and keyhole limpet hemocyanin (KLH) -IgG ICs were 
prepared by replacing oxLDL with nLDL or incubating rabbit anti-KLH antibody together 
with KLH, respectively. To prepare insoluble immune complexes containing human IgG, 
soluble immune complexes between oxLDL and human anti-oxLDL antibodies (either 
recombinant or isolated from serum) were further linked by the F(ab)2 fragment of goat anti-
human IgG. The endotoxin levels of oxLDL-IgG ICs and other proteins used in the 
experiments were analyzed by Limulus assay and found to contain endotoxin levels lower 
than 100 pg/ml of LPS. 
 
Determination of cell viability, proliferation, and apoptosis 
To analyze the viability of the cells, 50 µl of Cell Proliferation Reagent WST-1 was added to 
the cells, which were incubated for 1 h at +37°C in 5% CO2, and the production of formazan 
dye was quantified by measuring absorbance at 450 nm. To analyze cell proliferation, 
monocytes were cultured in the presence of [3H-methyl]-thymidine and then harvested on a 
TomTek harvester. Incorporated [3H-methyl]-thymidine was measured with a liquid 
scintillation counter. In the experiments designed to study apoptosis, the monocytes detached 
to the media were collected by centrifugation and analyzed together with the cells attached to 
the wells. Nuclear fragmentation and levels of active caspase-3 were analyzed by commercial 
ELISA-based methods. For annexin V staining, monocytes were cultured on glass slips, fixed 
with 1% paraformaldehyde, and incubated with Annexin V Fluos diluted in HEPES buffer. 
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V RESULTS AND DISCUSSION 
 
 
1 Complement activation in atherosclerosis 
 
1.1 Regulation of complement activation in atherosclerotic lesions (I and II) 
 
1.1.1 Factor H and C4bp are present in atherosclerotic lesions 
 
In an initial attempt to better understand the regulation of the complement system in 
atherosclerotic lesions, we analyzed the presence of two complement regulators, factor H and 
C4b-binding protein (C4bp), in different stages of atherosclerosis progression by 
immunohistochemical methods and compared their staining patterns with those of the 
activators of the complement system, the activation or inactivation products of the 
complement as well as the terminal membrane-attack complex (C5b-9). 
 
We found that factor H, the major inhibitor of the alternative pathway, was already present in 
normal intimas as a narrow subendothelial layer (Figure I, online supplement, in paper I). In 
contrast, positive staining was more extensive in atherosclerotic lesions. Thus, in early to 
intermediate lesions, factor H was present in the superficial intima, in which it showed strict 
colocalization with versican proteoglycan (Figure II, online supplement, and Figure 1, in 
paper I). This colocalization was observed in all early atherosclerotic lesions in which a 
distinct superficial proteoglycan-rich layer and a deep musculoelastic layer could be clearly 
distinguished. In contrast, in advanced atherosclerotic lesions, the staining for factor H was 
more extensive and diffuse, and showed only partial colocalization with versican 
proteoglycan. In all lesions, however, the deep intima did not stain for factor H. In addition to 
immunohistochemistry, we verified the presence of factor H and also other members of the 
factor H family by immunoblotting homogenates of human coronary arteries and aorta 
(Figure 5, in paper I). These analyses revealed that factor H and factor H-like protein-1 (FHL-
1), which is formed by an alternatively spliced mRNA of the factor H gene and shares the 
complement-regulatory properties of factor H, showed preferential retention in the intima 
when compared to their levels in plasma. Indeed, although it is likely that part of the intimal 
factor H derives from plasma through the endothelial layer, the increased levels of factor H 
may also result from the local synthesis of factor H by intimal cells, since at least 
macrophages and endothelial cells have been shown to be able to synthesize this complement 
inhibitor (Friese et al. 1999; Brooimans et al. 1989). Although factor H has been previously 
demonstrated in carotid lesions (Seifert & Hansson 1989), this was the first study to 
demonstrate factor H in human coronary arteries and show its colocalization with 
proteoglycans.  
 
Similarly to factor H, we found that C4bp, the major inhibitor of the classical complement 
pathway, was present both in normal intima and in atherosclerotic lesions of human coronary 
arteries. In the normal arterial intima, oonly the very subendothelial intima lining the vessel 
lumen showed a positive signal for C4bp, whereas in early to intermediate lesions, C4bp was 
clearly visible in the whole superficial layer of the intima with no positive staining in the 
deepest parts of the intima. In advanced lesions, C4pb showed a more diffuse and extensive 
staining pattern, but the deepest part of the musculoelastic layer again lacked staining for 
C4bp (Figure 1, in paper II). Furthermore, in the superficial area, C4bp colocalized with 
glycosaminoglycans, components of arterial proteoglycans (Figure 2A, in paper II). While the 
staining for C4bp was mostly extracellular, some cells in the superficial intima and adventitia 
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also showed positive staining for C4bp. These findings are consistent with some previous 
studies, which have shown that C4bp is present in atherosclerotic lesions of the human 
thoracic aorta (Kimoto et al. 1996), and which have also revealed mRNA for C4bp in arterial 
wall (Yasojima et al. 2001a). However, our study illustrates, for the first time, the presence of 
C4bp in the intima during different stages of coronary atherosclerosis and demonstrates its 
colocalization with arterial proteoglycans. 
 
In our study, in addition to learning about the lesional distribution of C4bp, we were also 
interested in whether C4bp would colocalize with protein S in the arterial wall. Protein S is a 
vitamin K-dependent cofactor in the anticoagulant system, and the majority of C4bp circulates 
as a complex with protein S (reviewed by Villoutreix et al. 1999). Double-
immunofluorescence staining revealed that C4bp and protein S colocalized in the extracellular 
space of the superficial intima, in addition to which similar colocalization was also observed 
in some subendothelial cells (Figure 5, in paper II). In addition, an intense cellular staining 
pattern for protein S was detected in the endothelial lining of the vessel wall, in majority of 
intimal cells, and especially in the media, which findings are consistent with the previous 
reports showing that protein S binds to endothelial cells (Hackeng et al. 1993) as well as with 
the reports on the synthesis of this protein by endothelial and vascular smooth muscle cells in 
vitro (Fair et al. 1986; Benzakour & Kanthou 2000). Of interest, the interaction of C4bp and 
protein S may also have some functional importance. Thus, upon the formation of this 
complex in the circulation, the anticoagulant activity of protein S is lost, whereas the 
functional properties of C4bp are not affected. In tissues, protein S has been suggested to bind 
to apoptotic cells and to increase their uptake by phagocytes. When present as a complex, 
protein S can also carry C4bp to the surface of apoptotic cells, which markedly decreases the 
uptake of apoptotic cells by phagocytes (Webb et al. 2002; Kask et al. 2004). However, the 
targeting of C4bp on the surface of apoptotic cells could still be beneficial, since it can 
prevent further complement activation, which would lead to secondary necrosis and increased 
inflammation. Interestingly, in our study, we could observe protein S colocalized with cleaved 
caspase-3-positive apoptotic cells. In addition, some apoptotic cells were positive also for 
C4bp (Figure 6, in paper II). These results suggest that protein S and C4bp could be involved 
in the regulation of the disposal of apoptotic cells and in diminishing the inflammatory 
response even in atherosclerotic lesions.  
 
The aim of this part of our study was to find out whether complement activation is regulated 
in atherosclerotic lesions. Regarding the inhibition of complement activation, factor H and 
C4bp play analogous roles in the alternative and classical pathways, respectively (see Figure 
3). More specifically, factor H binds C3b and thus inhibits the assembly and promotes the 
decay of alternative pathway C3 convertase and, in addition, acts as a cofactor for factor I in 
the proteolytic cleavage of C3b (Whaley & Ruddy 1976; Weiler et al. 1976; Pangburn et al. 
1977). By these mechanisms, factor H acts at the most critical step of the complement 
activation, the amplification loop, and is thus largely responsible for the prevention of 
uncontrolled complement activation. C4bp, in turn, inhibits the classical complement pathway 
by preventing the assembly and accelerating the decay of the classical pathway C3 convertase 
C4b2b and acting as a cofactor for factor I in the cleavage and inactivation of C4b (Gigli et al. 
1979). Thus, inhibition of complement activation via factor H and C4bp prevents the 
activation of the terminal complement pathway, but allows the generation of complement-
derived opsonins, i.e. the split products of C3 and C4.  
 
We initially observed that, in atherosclerotic coronary lesions, C4c/d and C3d, two products 
of complement activation by the classical and alternative pathways, respectively, did not 
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necessarily colocalize with the terminal product of complement activation, C5b-9 (Figure 1, 
in paper I; Figure 4, in paper II). More specifically, in early to intermediate lesions, C4c/d and 
C3d were present in the superficial proteoglycan-rich layer of the intima, whereas C5b-9 was 
found as distinct deposits deeper in the intimal musculoelastic layer with very little or no 
overlap with C4c/d or C3d. This finding suggested to us that, in the superficial intima, 
complement activation had been prevented from proceeding to the terminal C5b-9 level. 
Interestingly, as described above, both C4bp and factor H located specifically in this 
superficial area devoid of C5b-9, suggesting that these two regulators could have inhibited 
complement activation in the area. To obtain further evidence to support this hypothesis, we 
analyzed in more detail the spatial relationship between factor H or C4bp and C5b-9 by 
immunofluorescence double staining of sections of coronary arteries (Figure 2, in paper I; 
Figure 3, in paper II). Indeed, we found a reciprocal staining pattern for factor H or C4bp and 
C5b-9 in most of the samples studied. To obtain semiquantitative data, we adopted a scoring 
system for the analysis of the proportion of overlap between the areas positive for C5b-9 and 
factor H. We found that, in the samples with distinct stainings for factor H and C5b-9, about 
60% of the lesions showed almost fully reciprocal staining patterns (≤ 20% overlap), while 
25% showed some overlap (21-80% overlap), and only 12.5% showed colocalization between 
factor H and C5b-9 (>80% overlap). Similarly, overlap between C4bp and C5b-9 was very 
scarce, and in many cases their localization patterns were mutually exclusive. These novel 
findings suggested to us that complement activation in the arterial wall was regulated, and that 
the two soluble inhibitors, C4bp and factor H, could participate in this regulatory process.   
 
Taken together, our results suggested that both the classical and alternative pathways of 
complement were activated in atherosclerotic lesions. However, in the superficial intima, 
complement activation is limited to the C3 level and does not proceed to the assembly of 
terminal C5b-9. Furthermore, the superficial proteoglycan-rich layer of the intima contained 
inhibitors of the alternative and classical pathways, factor H and C4bp, respectively, 
suggesting that they could have inhibited complement activation in this area. To support this 
idea, these regulators showed a strictly reciprocal staining pattern with the complement 
terminal product C5b-9, which was found deeper in the musculoelastic layer of the intima. In 
addition, we could also show that CRP, which has the ability to initiate the classical 
complement pathway but also to terminate complement activation at the C3 level by binding 
factor H (Jarva et al. 1999), was present in the superficial intima, thus further supporting a 
role for factor H in the regulation of the complement in this layer of the human coronary 
arterial wall.  
 
1.1.2 Factor H and C4bp bind to arterial proteoglycans 
 
Since immunohistochemical analysis demonstrated that factor H and C4bp were located in the 
superficial intima and colocalized with arterial proteoglycans, we also tested for their ability 
to bind to arterial proteoglycans in vitro. Proteoglycans were isolated from human aorta and 
coupled to the NHS-activated HiTrap column, and the binding of factor H and C4bp to the 
column was analyzed by affinity chromatography (Figure 3B, in paper I; Figure 2B, in paper 
II). In addition, the surface plasmon resonance technique was used to analyze the binding of 
factor H (Figure 3A, in paper I). These analyses revealed that both factor H and C4bp bound 
to arterial proteoglycans. Addition of EDTA did not affect the binding, showing that these 
interactions were independent of the presence of Ca2+. Even though we could also detect CRP 
in the proteoglycan-rich layer of the intima, it did not bind to arterial proteoglycans in vitro 
(Figure III, online supplement, in paper I).  
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Previously, factor H has been shown to have three heparin-binding sites, one in each of its 
short consensus repeats 7, 9, and 20 (Pangburn et al. 1991; Blackmore et al. 1996; Blackmore 
et al. 1998; Ormsby et al. 2005), and it is thus likely that factor H binds to the 
glycosaminoglycan side chains of proteoglycans via one or more of these sites. Although the 
direct binding of factor H to arterial proteoglycans in affinity chromatography was relatively 
weak, it might still be physiologically significant because of the potentially multiple 
interactions between polymeric proteoglycans and factor H, and because the binding of factor 
H usually occurs after initial deposition of C3b, which can interact with factor H with three 
distinct sites (Cheng et al. 2006). Interestingly, the binding of heparin to factor H has been 
shown to potentiate the complement-inhibitory effect of factor H in the inactivation of C3b 
(Boackle et al. 1983).  
 
Similar to factor H, C4bp has also been shown to contain heparin-binding sites, which are 
located in the short consensus repeat 2 of each of the seven α-chains (reviewed by Blom 
2002). However, in contrast to factor H, the binding of soluble heparin glycosaminoglycan to 
C4bp actually inhibits its complement-regulatory properties. This is due to the fact that 
soluble heparin, by binding to each of the 7 heparin-binding sites in C4bp, prevents mutual 
binding of C4b and thereby inhibits the complement-regulatory function of C4b (Hessing et 
al. 1990). In contrast, the occupation of a restricted number of heparin-binding sites upon the 
binding of C4bp to immobilized glycosaminoglycans, like those in the arterial proteoglycan 
matrix, is the likely explanation for the ability of C4bp to exert its complement-regulatory 
function, as shown in our study. Similarly, various bacteria have been shown to bind C4bp to 
the heparin-like structures on their surface and in that way to protect themselves from 
complement-mediated killing by the host (reviewed by Blom et al. 2004).  
 
1.1.3 Arterial proteoglycans inhibit complement activation 
 
Since immunohistochemical analysis suggested that the proteoglycan-rich layer of the arterial 
wall is protected from the activation of the terminal complement pathway, and our in vitro 
experiments revealed that complement regulators bound to arterial proteoglycans, we 
hypothesized that arterial proteoglycans could be involved in the control of complement 
activation in atherosclerotic lesions. To study the role of proteoglycans in complement 
regulation, we undertook in vitro complement activation studies (Figure 4, in paper I). In 
these experiments we could show that, when coupled to Sepharose, both heparin and arterial 
proteoglycans were able to inhibit Sepharose-induced complement activation in human serum. 
By using another approach, we could show that heparin also inhibited complement activation 
induced by enzymatically modified LDL (E-LDL). Our findings are consistent with the 
previous reports, which have shown that heparin can inhibit complement activation 
(Kazatchkine et al. 1979), and they also add to the previous reports by showing similar effects 
for human arterial proteoglycans. Interestingly, the previous reports have shown that the 
inhibitory effect of heparin on complement activation appears to depend on its ability to bind 
to and potentiate the effect of factor H in the inactivation of C3b (Boackle et al. 1983).  
 
Only a few previous studies have linked the extracellular matrix of the arterial intima to the 
regulation of complement activation in the intima. Niculescu et al. examined the relationship 
between C5b-9 and the complement inhibitor S-protein/vitronectin in atherosclerotic lesions 
(Niculescu et al. 1989). S-protein/vitronectin prevents C5b-9 insertion in the cell membrane 
by binding to C5b-7, which is then followed by generation of cytolytically inactive sC5b-9 
complex. Using immuno-electron microscopy, they showed that S-protein/vitronectin 
appeared to associate with the connective tissue matrix, especially elastin fibers and collagen 
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bundles, and that cell debris in the vicinity of elastin also contained intense deposits of S-
protein/vitronectin. In addition, all cell debris was positive for C5b-9, suggesting that at least 
some of it colocalized with S-protein/vitronectin. Thus, the results suggested that, by 
associating with S-protein/vitronectin, the connective tissue matrix plays a role in the 
regulation of the terminal complement pathway in atherosclerotic lesions. In addition, 
Hindmarsh et al. showed that the subendothelial extracellular matrix produced by human 
endothelial cells in vitro is protected from complement activation by strongly bound decay-
accelerating factor (DAF), an inhibitor of both classical and alternative pathway C3 
convertase (Hindmarsh & Marks 1998).  
 
In summary, our findings suggested that the proteoglycan-rich layer of the arterial wall 
contains matrix-bound complement inhibitors, inhibits complement activation in vitro, and 
forms a protective area in which complement activation is restricted to the C3 level (Fig. 5). 
These results are novel and implicate that not only complement activation, but also inhibition, 
may play a role in atherogenesis. The exact effect of such inhibition of the complement 
system on the development of atherosclerosis is not fully understood. Based on the current 




Fig. 5. Regulation of the complement system in atherosclerotic lesions. Our results suggested that, in the 
superficial proteoglycan-rich layer, which contained factor H and C4bp, complement activation was limited to 
the C3 level. Thus, although this area contained both activators of the complement system (IgM, CRP) and 
markers of activation via the classical (C4c) and alternative pathways (properdin), no terminal C5b-9 was 
present in the area. In the musculoelastic layer, possibly due to the absence of proper regulation, complement 
activation had proceeded to the assembly of C5b-9. Our results, which demonstrated the presence of properdin, 
but not C4c, in this area, suggested that C5b-9 had been generated as a result of activation of the alternative 
pathway of the complement. Previously, this area has been shown to contain modified lipids, which are known to 
activate complement via the alternative pathway.  
Results and Discussion 60 
the terminal level could be beneficial in atherogenesis by inhibiting the generation of pro-
inflammatory C5a and C5b-9, but still allowing the generation of the opsonins C4b, C3b, 
iC3b, and C3d. Unfortunately, no experimental animal studies investigating the role of 
complement regulators in atherosclerosis exist. In humans, deficiencies of complement 
regulators are relatively uncommon. Genetic deficiency of factor H (about 20 cases described) 
leads to strongly decreased factor H levels in plasma, predisposes to bacterial infections, and 
causes haemolytic uremic syndrome (Thompson & Winterborn 1981) and glomerulonephritis 
(Levy et al. 1986). In patients with glomerulonephritis, the glomerular basement membranes, 
normally protected by extracellular matrix-bound factor H contain intense deposits of 
complement. Thus, our findings extend these findings and suggest that factor H also protects 
the proteoglycan-rich layer of the arterial intima from the complement attack. Unfortunately, 
no data are available regarding cardiovascular diseases in the small number of factor H-
deficient patients. However, recent studies have investigated whether Y402H gene 
polymorphism of factor H, which locates within the binding site for heparin and C-reactive 
protein, plays a role in thromboembolic events. In two case-control studies, no evidence of an 
association between this polymorphism and the risk of incident of MI and ischemic stroke 
(Zee et al. 2005) or angiographically-verified coronary artery disease (Goverdhan et al. 2006) 
could be detected. In contrast, a prospective study comprising more than 5000 healthy 
individuals could show that Y402H polymorphism was associated with an increased risk for 
myocardial infarction (Kardys et al. 2006), and supports the notion that factor H may have an 
important, protective role in atherogenesis. Genetic C4bp deficiency in humans is even more 
rare than factor H deficiency, and it associates with angioedema while no reports regarding 
atherosclerosis in these patients exist (Trapp et al. 1987).  
 
1.1.4 C5b-9 is produced mainly via the alternative pathway 
 
We found that the complement system had proceeded to its completion, i.e. to the generation 
of C5b-9, only in the deep musculoelastic layer of the intima, and that this was probably due 
to the absence of the complement regulators factor H and C4bp. However, the pathway - 
either classical or alternative - leading to the generation of C5b-9 in atherosclerotic lesions 
has not been fully clarified. Indeed, while no evidence of complement activation via the lectin 
pathway exist, various structures and molecules capable of activating either the classical or 
alternative pathway as well as signs of complement activation via these pathways have been 
detected in atherosclerotic lesions. In contrast, normal arterial intima lacks signs of 
complement activation, suggesting that complement-activating structures are either generated 
or deposited in the arterial wall during atherogenesis.  
 
To investigate which pathway of complement activation was responsible for the generation of 
C5b-9 in the arterial intima, we compared the staining patterns of C4 and properdin, markers 
of classical and alternative pathway activation, respectively, with the staining pattern of the 
terminal membrane-attack complex (C5b-9) (Figure 4, in paper II). The superficial intima 
contained both C4c and properdin, suggesting that both the classical and alternative pathways 
had been activated in this area. In contrast, this area was devoid of C5b-9, likely reflecting the 
action of the complement inhibitors factor H and C4bp. Thus, only the deep musculoelastic 
layer contained C5b-9. Interestingly, this area was negative for C4c/d but strongly positive for 
properdin, suggesting that activation of the alternative pathway was responsible for the 
generation of C5b-9 in this area. Previous studies have shown that the deep intima contains 
enzymatically-modified LDL, which is known to activate the alternative pathway of 
complement (Torzewski et al. 1998b), hence rendering these modified LDL particles possible 
candidates for the observed activation of complement by the alternative pathway. We could 
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also demonstrate that, in the deep musculoelastic layer, C5b-9 does colocalize with 
cholesterol crystals, which are known to activate the alternative pathway of complement (Fig. 
6, Oksjoki et al., unpublished observation). In addition, it was found recently that immune 
complexes, which are traditionally regarded as activators of the classical complement 
pathway, also increase the activation of the alternative complement pathway by stabilizing C3 
convertase (Ji et al. 2002). Thus, it is possible that immune complexes, which have been 
shown to be present in the arterial wall (Ylä-Herttuala et al. 1994), could participate in the 





Figure 6. Complement terminal product C5b-9 (black) is deposited in the deep musculoelastic layer of the 
arterial wall, where it cololocalizes with extracellular cholesterol crystals (white clefts; marked with arrows). 
 
 
Taken together, our findings suggest that activation of the alternative pathway is responsible 
for the generation of C5b-9 and thus, add to the current understanding of the mechanisms of 
complement activation in atherosclerotic lesions. In addition, our results support the 
hypothesis that, in atherosclerotic lesions, modified lipoproteins trigger complement 
activation leading to the generation of pro-inflammatory C5b-9. 
 
 
1.2 Receptors for anaphylatoxin are expressed in atherosclerotic lesions (III) 
 
Complement activation via any of the three pathways leads to the release of two potent 
anaphylatoxins, C3a and C5a. Both anaphylatoxins act on their target cells by binding and 
signaling through their ligand-specific receptors, which belong to the family of seven 
transmembrane domain G-protein-coupled receptors. Since complement is activated in 
atherosclerotic lesions, and anaphylatoxins are thus locally produced, we were interested to 
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learn whether the cells of human coronary arteries would express receptors for the two 
anaphylatoxins, C3a and C5a. Our immunohistochemical and PCR analyses revealed that 
these receptors, although almost absent from normal coronary intimas, were highly expressed 
in atherosclerotic lesions (Figure 1, in paper III). 
 
To further characterize the cell types expressing these receptors in the lesions, we performed 
double immunofluorescence staining with antibodies against anaphylatoxin receptors and 
different cell types of the intima (Figures 2 and 3, in paper III). The major cell type expressing 
both C3aR and C5aR in the intima was the macrophage. Since intimal macrophages derive 
from circulating monocytes, we also investigated the expression of C3aR and C5aR during 
the maturation of human blood monocytes into macrophages in culture. We observed that 
freshly isolated monocytes expressed low but detectable levels of both C3aR and C5aR, and 
that during their maturation into macrophages, the expression of both receptors significantly 
increased, although the kinetics of the increase differed markedly between the two types of 
receptors. Our findings are consistent with the previous reports demonstrating that cells of 
monocyte–macrophage lineage express these receptors (Martin et al. 1997; Gerard & Gerard 
1991), and that the expression of these receptors is increased after PMA-induced 
differentiation and activation of THP-1 cells (Gasque et al. 1998) and U937 cells (Crass et al. 
1996) into macrophage-like cells. Regarding other inflammatory cells of the intima, the 
expression of C3aR and C5aR were more variable. Thus, while all T cells expressed C5aR, 
only about 1/10th of them expressed C3aR. Previous reports have shown that circulating, 
unstimulated T cells express C5aR (Nataf et al. 1999), whereas activation of T cells is needed 
for them to express C3aR (Werfel et al. 2000). Thus, it is likely that the C3aR-positive T cells 
in the lesions are in an activated state. Moreover, all mast cells expressed C5aR, but none of 
them expressed C3aR. This lack of C3aR in mast cells was unexpected, since cells of the 
immature human mast cell line HMC-1 have been shown to express functional C3aR 
(Zwirner et al. 1998a) and moreover, human skin mast cells have been shown to respond to 
C3a by degranulation (Wuepper et al. 1972). However, no immunohistochemical reports on 
the presence of C3aR in human mast cells are available, and the functional effects of C3a on 
mast cells are assumed to be due to direct stimulation of G-proteins by this peptide (Mousli et 
al. 1992; Fukuoka & Hugli 1990). We also looked for the presence of C3aR in the mast cells 
of normal skin, inflamed intestinal wall and inflamed tonsils. All the mast cells in skin and 
intestine were negative, whereas a fraction of tonsillar mast cells were positive for C3aR. 
Hence, tissue-specific differences in the expression of C3aR in mast cells exist. Finally, in 
addition to inflammatory cells, both endothelial cells and superficial smooth muscle cells, but 
not those of deep intima or media, expressed C3aR and C5aR. This limited expression of 
anaphylatoxin receptors in smooth muscle cells may reflect the fact that a phenotypic switch 
from contractile to matrix-synthesizing cells is required for smooth muscle cells to be able to 
express these anaphylatoxin receptors. 
 
Table 8. Summary of the expression of anaphylatoxin receptors by cells of human 
coronary atherosclerotic lesion 
      
 macrophages T cells mast cells smooth muscle cells endothelial cells 
C3aR + +  (about 1/10th) - superficial + 
C5aR + + + superficial + 
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Signaling through anaphylatoxin receptors, especially C5aR, has been shown to mediate 
effects that potentially promote atherosclerosis and also affect the stability of the plaque. 
Thus, both anaphylatoxins may be involved in the recruitment of inflammatory cells into the 
intima by acting as chemokines (Arend et al. 1989; Zwirner et al. 1998b; Hartmann et al. 
1997) and by upregulating the expression of adhesion molecules on endothelial cells 
(Foreman et al. 1996; Albrecht et al. 2004). In addition, both anaphylatoxins can induce 
activation and expression of pro-inflammatory cytokines by other intimal cells (Takabayashi 
et al. 1998; Takabayashi et al. 1996; Goodman et al. 1982; Ember et al. 1994; Albrecht et al. 
2004; Monsinjon et al. 2003; Schulman et al. 1988; el-Lati et al. 1994). In addition, activation 
of mast cells and macrophages through C5aR has been shown to play a major causal role in 
triggering experimental immune complex-induced disease (Bozic et al. 1996; Hopken et al. 
1997; Godau et al. 2004; Baumann et al. 2001; Shushakova et al. 2002), which may also be 
relevant for the progression of atherosclerosis, since immune complexes have been shown to 
be deposited in atherosclerotic intima (Ylä-Herttuala et al. 1994). Furthermore, previous 
studies have demonstrated that anaphylatoxins are spasmogenic to arteries (Vogt 1986). 
However, we found that smooth muscle cells of the contractile phenotype in the arterial wall, 
i.e. in the deep intima and the media, did not express anaphylatoxin receptors. Indeed, it has 
been suggested that spasmogenic effects by anaphylatoxins could actually be mediated only 
indirectly, i.e. by the vasoactive products released from macrophages and mast cells in 
response to their activation by anaphylatoxins (Marceau et al. 1990). Although C3a and C5a 
mostly promote similar responses, some opposing effects have also been reported. Thus, 
while C5a promotes adaptive immunity (Morgan et al. 1983) and drives Th1 type 
proatherogenic immune responses, C3a mediates immunosuppressive effects (Morgan et al. 
1982) and drives Th2 type immune responses (Hawlisch et al. 2004), which, in turn, have 
been suggested to mediate antiatherogenic effects.  
 
Taken together, we found anaphylatoxin receptors to be present in atherosclerotic lesions, in 
which they were concentrated in the shoulder areas containing the infiltrate of inflammatory 
cells. This novel finding implicates, that anaphylatoxins could participate in the activation of 
intimal cells and thus affect the inflammatory status, and possibly also stability, of the plaque. 
In support of this notion, high levels of circulating anaphylatoxins have been reported in 
patients with acute coronary syndromes compared to those with stable coronary artery disease 
(Kostner et al. 2005), and moreover, elevated plasma levels of C5a have been shown to 
independently predict future major adverse cardiovascular events in patients with established 
atherosclerosis (Speidl et al. 2005).  
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2 OxLDL-IgG immune complexes induce survival of human monocytes (IV) 
 
 
One potential group of complement activators in atherosclerotic lesions include immune 
complexes, and a recent study verified that also autoimmune oxLDL-complexes are able to 
activate the complement via the classical pathway (Saad et al. 2006). OxLDL-IgG immune 
complexes have been detected in the circulation of humans, and lipoprotein-containing 
immune complexes have also been isolated from atherosclerotic lesions (Ylä-Herttuala et al. 
1994). Regarding atherosclerosis, the role of such immune complexes is not fully clarified. It 
has been suggested that that the formation of these complexes could be involved in the 
removal of harmful oxLDL from the circulation via recognition of the complexes by 
phagocyte Fcγ receptors. However, a recent paper by Reardon and coworkers suggested these 
immune-mediated mechanisms do not seem to play a role in the clearance of modified LDL 
from plasma, at least in apoE-/- mice (Reardon et al. 2004). In contrast, it has been shown that 
lipoprotein-containing immune complexes can have many potentially proatherogenic effects 
on intimal cells. Thus, in addition to activating the complement, oxLDL-containing immune 
complexes have been shown, when added to cultured macrophages, to promote foam cell 
formation (Griffith et al. 1988; Lopes-Virella et al. 1997) and to induce the production of 
proinflammatory cytokines (Saad et al. 2006), oxygen radicals (Virella et al. 1995), and 
matrix metalloproteinases by macrophages (Huang et al. 2000). In addition, a prospective trial 
involving diabetic subjects suggested that high concentrations of LDL-ICs predicted the 
development of coronary artery disease (Lopes-Virella et al. 1999). In our study, we wanted 
to further investigate the potential roles of oxLDL-IgG immune complexes in atherogenesis. 
A previous study by Marsh et al. (Marsh et al. 1999) demonstrated that immobilized IgG 
molecules induced the production of monocyte colony-stimulating factor (M-CSF) by human 
monocytes. Accordingly, we hypothesized that oxLDL-IgG immune complexes (oxLDL-IgG 
ICs), in which IgG-molecules are bound to lipoprotein particles, could affect monocyte 
survival.  
 
In our design of the study, we took into account the previous results suggesting that the size of 
immune complexes (ICs) is a critical factor in determining their biolocigal activity. Thus, 
previous studies have suggested that soluble (small) ICs, in contrast to immobilized ICs or 
insoluble (large) ICs, poorly cross-link Fcγ receptors and show decreased biologic activity 
(Jarvis et al. 1999). While circulating oxLDL-IgG ICs are mainly soluble, the arterial intima 
is likely also to contain immobilized oxLDL-IgG ICs, since at least part of oxLDL is matrix-
bound via LPL (reviewed by Pentikäinen et al. 2002). Thus, to mimic such arterial 
immobilized ICs, we prepared ICs by 1) incubating rabbit IgG against human LDL together 
with oxLDL or 2) creating soluble ICs containing oxLDL and either human recombinant or 
serum derived anti-oxLDL antibodies, and bridging the formed soluble ICs together with 
F(ab)2 fragments of goat anti-human IgG.  
 
Our results showed that addition of oxLDL-IgG ICs to monocytes cultured in the absence of 
growth factors altered the morphology of monocytes and promoted their survival. Thus, 
monocytes cultured in the presence of oxLDL-IgG ICs remained attached to the surface of the 
well, were large, and spread along the surface of the well in contrast to the detachment and 
shrunken morphology of untreated control cells (Figure 1A, in paper IV). Further analysis by 
Oil Red staining and HPTLC revealed that oxLDL-IgG IC treatment transformed monocytes 
into foam cells (Figure II, online supplement, in paper IV). The uptake of complexes seemed 
to be mediated via the immunoglobulin part of the complexes, since the addition of oxLDL or 
acetyl LDL alone did not increase the content of intracellular cholesterol of monocytes. Thus, 
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the uptake of oxLDL in the form of immune complexes revealed a new mechanism, by which 
monocytes can already become transformed into foam cells at the stage when they do not 
express the scavenger receptors essential for the uptake of modified lipoproteins. This 
observation suggests that the process of foam cell formation may already begin early after the 
infiltration of blood monocytes into the subendothelial space of inflamed arterial intima. In 
addition to foam cell formation, the number of viable monocytes was significantly increased 
in response to oxLDL-IgG IC treatment (Figure 1B and Figure 6, in paper IV). Although 
previous studies had suggested that oxLDL alone could have survival-promoting effects in 
monocytes, we failed to detect such effects for oxLDL alone. Rather, our results, which 
demonstrated that immune complexes containing native LDL or KLH are able to induce 
similar increases in the number of viable monocytes, suggested that the survival-promoting 
effect of oxLDL-IgG ICs is mediated via IgG molecules (Figure 1C, in paper IV).  
 
Regarding the increased viability of monocytes, we were interested to learn more about the 
mechanisms by which oxLDL-IgG ICs promote monocyte survival. First, we investigated 
whether the increased viability of monocytes in response to oxLDL-IgG IC treatment resulted 
from increased cellular proliferation or decreased apoptosis of cells. As demonstrated by the 
lack of incorporation of radioactive-labeled thymidine into nucleic acids, no proliferation in 
response to oxLDL-IgG ICs was observed. Rather, our results confirmed that oxLDL-IgG ICs 
protected monocytes from apoptotic cell death. Thus, following the addition of oxLDL-IgG 
ICs to monocytes, the amount of active caspase-3 and DNA fragmentation were reduced to 
levels comparable to cells cultured merely in the presence of growth factors, either M-CSF or 
GM-CSF (Figure 2, in paper IV).  According to our original hypothesis, oxLDL-IgG ICs also 
induced a concentration-dependent increase in the production of M-CSF by monocytes 
(Figure 3A, in paper IV). Upon secretion, M-CSF may, in an auto- and paracrine manner, 
increase cellular survival by activating the PI 3-kinase-dependent pathway, resulting in the 
phosphorylation of Akt, a central survival factor in monocytes (Kelley et al. 1999). To our 
surprise, however, the production of M-CSF did not seem to be essential for the survival-
promoting effects of oxLDL-IgG ICs. Thus, the neutralizing anti-M-CSF antibody did not 
affect IC-induced monocyte survival, while it efficiently blocked the effect of externally 
added M-CSF on monocyte survival (Figure 3B, in paper IV). Of interest, cross-linking of 
mouse Fcγ receptors (FcγRs) with monoclonal antibodies has also been shown to lead to PI 3-
kinase activation and Akt phosphorylation in mice (Cao et al. 2004). Accordingly, we 
hypothesized that oxLDL-IgG immune complexes could mediate their effect on monocyte 
survival by direct binding to FcγRs with subsequent activation of Akt. Indeed, rapid 
phosphorylation of Akt after the addition of oxLDL-IgG ICs and the inhibition of monocyte 
survival by blocking the Akt-pathway strongly supported the direct activation of Akt via Fcγ 
receptors as the anti-apoptotic mechanism of immune complexes (Figure 4, in paper IV). 
Furthermore, experiments with receptor blocking antibodies revealed that the observed effect 
was mainly mediated by FcγRI (Figure 5, in paper IV). This is in line with the previous results 
showing the involvement of FcγRI and II in the uptake of and signaling induced by oxLDL-
containing ICs in U936 and THP-1 cell lines and in human monocyte-derived macrophages 
(Huang et al. 2000; Lopes-Virella et al. 1997; Huang et al. 1999). Taken together, our 
findings reveal a novel mechanism by which oxLDL-IgG ICs can promote monocyte-
macrophage accumulation in arterial intima, and thus, affect the pathogenesis of 
atherosclerosis. 
 
Regarding atherosclerosis, previous studies have shown that apoptotic macrophages occur in 
atherosclerotic lesions, and that extensively oxidated LDL is strongly pro-apoptotic (reviewed 
by Martinet & Kockx 2001). In contrast, a very recent paper demonstrated that minimally 
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oxidized LDL (mmLDL), which was prepared by exposure of LDL to cells overexpressing 
15-lipoxygenase, protected macrophages from apoptosis induced by both oxLDL and free 
cholesterol loading (Boullier et al. 2006). Of interest, the mmLDL-induced activation of 
PI3K/Akt-pathway and the blocking of this pathway completely eliminated the pro-survival 
effect of mmLDL. Thus, it is interesting to hypothesize that minimally modified LDL as well 
as oxLDL-IgG immune complexes could mediate survival-promoting effects in the lesions 
and thus to protect monocytes from the death-promoting effects of other factors, e.g. highly 
oxidized LDL.   
 
What might be the implications of increased monocyte survival/apoptosis for the development 
of atherosclerosis? Obviously, increased monocyte survival tends to increase and maintain the 
intimal macrophage population. Various studies have suggested that, depending on the stage 
of the disease, macrophage survival/death may have opposing effects on atherogenesis and 
may be major determinants of lesion development (reviewed by Tabas 2005). To support the 
pro-atherogenic role of macrophages, previous studies have shown that apoE-/- mice that lack 
M-CSF, and therefore also lack tissue macrophages, show decreased atherosclerosis. In 
addition, deficiency of the p53 tumor-suppressor gene in macrophages, which leads to 
decreased macrophage apoptosis or increased proliferation, leads to increased lesion size in 
apo*3-Leiden mice (van Vlijmen et al. 2001) and LDLR-/- mice (Merched et al. 2003), 
respectively, and also causes the development of a more vulnerable lesion type. Similarly, 
lack of the proapoptotic protein Bax in macrophages, which leads to their decreased 
apoptosis, increases atherosclerosis in LDLR-/- mice (Liu et al. 2005). The authors of the 
study suggested that macrophage apoptosis provides a critical self-defence mechanism in 
suppressing atherosclerosis, since macrophage death may limit the number of inflammatory 
cells and thus also the local inflammation and synthesis of matrix metalloproteinases in the 
lesions. However, this may be true only if the apoptotic bodies of dying macrophages are 
cleaned efficiently by the neighboring phagocytes, which appears to be the case in early 
lesions. However, in more advanced atherosclerotic lesions, the uptake of apoptotic cells is 
impaired (Schrijvers et al. 2005), which may lead to secondary necrosis and the formation of 
a necrotic core and the accumulation of debris in intima. Thus, in early lesions, in which the 
uptake of apoptotic cells is still efficient, macrophage apoptosis may exert atheroprotective 
effects, whereas in advanced lesions with defective uptake, macrophage apoptosis might 
promote the generation of a necrotic core with a concomitant proinflammatory response 
(Tabas 2005).  
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3 Future perspectives 
 
 
According to the current concepts, atherosclerosis is a chronic inflammatory state of the 
vessel wall with an autoimmune response against either foreign or altered self-structures 
present in the lesions. Despite the dramatic increase in the knowledge about the role of 
immune mechanisms in the pathogenesis of atherosclerosis during the past decades, our 
understanding of the complex role of the immune response in atherogenesis still remains 
rather fragmentary. Animal studies have established that activation of the immune response 
can have both protective (= anti-atherogenic) and adverse (= proatherogenic) effects in 
atherogenesis, and these effects may vary at different stages of the disease. However, 
elucidation of the role of specific parts of immunity could lead to insights into their potential 
roles as targets of therapeutic interventions. Thus, therapeutic interventions that specifically 
suppress the adverse, proatherogenic types of immunological responses or specifically 
strengthen the beneficial, anti-atherogenic types of responses could emerge as new ways of 
combating this disease. Although immune interventions in experimental animals have 
provided promising results, the relevance of these observations to human disease remains to 
be determined. When contemplating these issues, it is of special importance to keep in mind 
that immune responses have extremely important functions in the protection of the host 
against pathogens. Thus, it would be essential to be able to pharmacologically target the 
process of atherosclerosis without interference of the physiologically meaningful functions of 
the immune response. The following paragraphs discuss the role of complement system and 
immune response against plaque antigens, notably oxLDL, as possible therapeutic targets.   
 
Regarding the complement system, experimental studies have suggested that complement 
activation, at least to its completion, is potentially proatherogenic. In addition, clinical human 
studies have suggested a correlation between increased levels of anaphylatoxins or C5b-9 and 
acute coronary events. It is therefore intriguing that that various inhibitors of the complement 
system and anaphylatoxin receptors have been recently generated. These drugs have already 
been tested in phase II-III human studies for the treatment of several inflammatory and 
autoimmune diseases, such as rheumatoid arthritis, asthma, psoriasis, nephritis, 
dermatomyositis, systemic lupus erythematosus, and paroxysmal nocturnal hematuria 
(Holland et al. 2004). In patients undergoing cardiopulmonary by-pass operation, the soluble 
complement receptor type 1 (Lazar et al. 2004) and the humanized monoclonal anti-C5 
antibody (pexelizumab) (Verrier et al. 2004) have been shown to decrease mortality and the 
incidence of myocardial infarction. In addition, pexelizumab, which blocks the generation of 
both C5a and C5b-9, has already been used in clinical trials for acute myocardial infarction, 
and 24-h infusion was shown to significantly reduce 90-day mortality in patients undergoing 
angioplasty by attenuating the inflammatory response (Granger et al. 2003). Indeed, the 
effects of pexelizumab in conjunction with angioplasty in acute myocardial infarction are 
currently being studied in the APEX-AMI trial, which aims to recruit 8500 patients 
(Armstrong et al. 2005). It is also intriguing to hypothesize that orally administered 
anaphylatoxin-receptor antagonists could be used in the treatment of chronic inflammatory 
conditions such as atherosclerosis. In addition to having an easier route of administration, 
they have another advantage over the C5-inhibitor: they specifically block the interactions 
between C5a and C3a and their respective receptors and thus leave intact the other 
complement effector mechanisms necessary for immune protection. 
 
During recent years, much attention has also been paid to the possibility to use the immune 
response against oxLDL as a therapeutic target. Thus, the fascinating idea of the possibility to 
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vaccinate against atherosclerosis has risen from several studies, which have provided 
evidence that immunization with atherosclerosis-related antigens such as oxLDL can affect 
atherogenesis in experimental animals. Indeed, in mouse models of atherosclerosis, parenteral 
immunization with preparations of oxidized LDL has been shown to evoke an 
atheroprotective immune response and thus, reduce the extent of the plaques up to 40-70%. 
To further characterize the epitopes leading to protective immunity, Fredrikson et al. recently 
demonstrated that some of the 20-amino acid peptide sequences of apoB-100 (both native and 
MDA-modified), against which humans have been shown to developed immune response, 
also reduced the extent of atherosclerotic lesions in a mouse model when administered in the 
vaccine formulation (Fredrikson et al. 2003b; Fredrikson et al. 2005). In addition to 
decreasing the lesion size, immunization also led to a more stable plaque phenotype as 
reflected by the decrease in the number of macrophages and increase in the content of 
collagen. Furthermore, the immune response was characterized by a shift towards 
antiatherogenic Th2-type of immune response as suggested by the significant increase in the 
Th2-type antibody IgG1. Interestingly, also passive immunization with human IgG1 generated 
against MDA peptide sequences reduced atherosclerosis in apoE-/- mice (Schiopu et al. 
2004). In addition to apoB-100 peptides, also phosphorylcholine present in oxLDL has been 
suggested to provoke an atheroprotective immune response, which is characterized by the 
generation of IgM natural antibodies. As phosphorylcholine is part of the S. pneumoniae cell 
wall, Binder et al. hypothesized and could show that immunization with S. pneumoniae 
induced an increase in phosphorylcholine antibodies, which, likely by cross-reacting with 
oxLDL, reduce atherosclerosis in LDLR-/- mice (Binder et al. 2003). These promising results 
have generated optimism concerning vaccination with epitopes of oxLDL as a future 
therapeutic option in the combat against atherosclerosis. However, before applying this 
strategy to humans, various issues need to be clarified, i.e. the key antigenic determinants 
involved in atherosclerosis, the most suitable adjuvant and route of administration, and the 
safety and durability of the effect. In contrast to oxLDL, immunological tolerance against 
HSP60/65 and β2GPI through activation of mucosal immunity has been shown to lead to 
decreased atherosclerosis in animal models (Maron et al. 2002; George et al. 2004). This 
atheroprotective effect is likely to involve the activation of regulatory T cells. Similarly, 
induction of mucosal tolerance against disease-related antigens has been shown to be efficient 
in decreasing autoimmune diseases in experimental animals as well as in humans (Faria & 
Weiner 2005). Thus, approaches based on the induction of oral tolerance for disease-related 
antigens could also emerge as a new immunomodulatory therapy for atherosclerosis. 
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VI SUMMARY AND CONCLUSIONS 
 
 
Current evidence indicates that immune mechanisms play a role in atherogenesis. The purpose 
of this study was to examine the activation and regulation of one immune mechanism, the 
complement system, in atherosclerotic lesions, and to investigate the effects of oxLDL-
containing immune complexes on the survival of cultured human monocytes. Based on our 
results, the following summary and conclusions can be presented: 
 
1. The regulators of the alternative and classical pathways of the complement system, factor H 
and C4bp, respectively, were present in the human coronary arterial intima during all stages 
of atherosclerosis. In early to intermediate lesions, these inhibitors were located in the 
superficial intima, where they colocalized with arterial proteoglycans. In addition, both factor 
H and C4bp were able to bind to human aortic proteoglycans in vitro.   
 
2. Immunohistochemical evidence suggested that, in the superficial proteoglycan-rich layer of 
the intima, which contained factor H and C4bp, complement activation was limited to the C3-
level. Thus, although this area contained both activators of the complement system (IgM, 
CRP) and also markers of activation via the classical (C4c/d) and alternative pathways (C3d, 
properdin), no terminal C5b-9 was present in the area. In contrast, C5b-9 was present in the 
deep musculoelastic layer of the intima and showed very little overlap with factor H and 
C4bp.  
 
3. Since the results of immunohistochemistry suggested that the proteoglycan-rich layer of the 
coronary intima was protected from full-blown complement activation, we tested for the 
ability of arterial proteoglycans to regulate complement activation in vitro. We found that 
both arterial proteoglycans and heparin glycosaminoglycan were able to inhibit complement 
activation in human serum. The results suggested to us that, in the superficial intima, 
proteoglycans bind the complement inhibitors C4bp and factor H and thus, may block the 
complement activation from proceeding to the terminal level.  
 
4. In the musculoelastic layer of the intima, possibly due to the absence of regulation, 
complement activation proceeded to the assembly of C5b-9. Our results, which demonstrated 
the presence of properdin, but not C4c/d, in this area suggested that C5b-9 was generated as a 
result of activation of the alternative pathway of the complement.  
 
5. Complement activation generates two potent anaphylatoxins, C3a and C5a. Here we 
showed that, in contrast to normal intima, the cells of atherosclerotic lesions expressed the 
anaphylatoxin receptors C3aR and C5aR and thus had the potential to respond to 
anaphylatoxins. The major cell type expressing these receptors in the lesions was the 
macrophage. In addition, endothelial cells and superficial smooth muscle cells expressed both 
C3aR and C5aR, all T cells expressed C5aR, and a small fraction of them also expressed 
C3aR, whereas mast cells only expressed C5aR. These findings suggest that anaphylatoxins 
can play a role in atherogenesis and its complications.  
 
6. During atherogenesis, lipoprotein-containing immune complexes are deposited in the 
arterial wall and able to activate the classical pathway of the complement. We were able to 
show that oxLDL-IgG immune complexes induced survival of human monocytes by 
decreasing their spontaneous apoptosis. This effect was mediated via crosslinking of the Fcγ 
receptor I with subsequent activation of the Akt-dependent signaling pathway. In addition, the 
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oxLDL-IgG immune complexes transformed human monocytes into foam cells, and this 
already occurred at the stage when the expression of scavenger receptors and, thus, the uptake 
of modified lipoproteins alone are known to be very low. Modulation of monocyte survival 
may affect the genesis and maintenance of the intimal macrophage population, which, based 





Fig. 7. Summary of the results. We found that, in the superficial proteoglycan-rich layer, both the classical and 
alternative complement pathways had been activated, possibly via CRP, immune complexes, and modified 
lipoproteins. However, in this area, complement activation had been restricted to the C4c and C3d –levels, 
suggesting that complement activation was regulated. Indeed, regulators of the classical and alternative 
pathways, C4bp and factor H, respectively, were present in this specific area and bound to arterial proteoglycans 
in vitro. In addition, arterial proteoglycans could inhibit the activation of complement in vitro, an effect mediated 
probably via their interaction with complement inhibitors. Deeper in the intima, without C4bp and factor H, 
complement activation had proceeded to the terminal C5b-9-level via activation of the alternative pathway. In 
this area, C5b-9 may exert proinflammatory effects on various intimal cells. In addition, we detected expression 
of the receptors for complement-derived anaphylatoxins on intimal cells. Finally, we found that oxLDL-IgG ICs, 
in addition to transforming monocytes into foam cells, promoted their survival by decreasing their spontaneous 
apoptosis in an FcγR-dependent manner. 
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